The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.

Adult Endocrinology / standards Evidence-Based Medicine / standards Humans Thyroid Diseases / surgery Thyroidectomy / standards United States

Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
03 2020
Historique:
entrez: 22 2 2020
pubmed: 23 2 2020
medline: 12 5 2020
Statut: ppublish

Résumé

To develop evidence-based recommendations for safe, effective, and appropriate thyroidectomy. Surgical management of thyroid disease has evolved considerably over several decades leading to variability in rendered care. Over 100,000 thyroid operations are performed annually in the US. The medical literature from 1/1/1985 to 11/9/2018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines. The authors used the best available evidence to construct surgical management recommendations. Levels of evidence were determined using the American College of Physicians grading system, and management recommendations were discussed to consensus. Members of the American Association of Endocrine Surgeons reviewed and commented on preliminary drafts of the content. These clinical guidelines analyze the indications for thyroidectomy as well as its definitions, technique, morbidity, and outcomes. Specific topics include Pathogenesis and Epidemiology, Initial Evaluation, Imaging, Fine Needle Aspiration Biopsy Diagnosis, Molecular Testing, Indications, Extent and Outcomes of Surgery, Preoperative Care, Initial Thyroidectomy, Perioperative Tissue Diagnosis, Nodal Dissection, Concurrent Parathyroidectomy, Hyperthyroid Conditions, Goiter, Adjuncts and Approaches to Thyroidectomy, Laryngology, Familial Thyroid Cancer, Postoperative Care and Complications, Cancer Management, and Reoperation. Evidence-based guidelines were created to assist clinicians in the optimal surgical management of thyroid disease.

Sections du résumé

OBJECTIVE
To develop evidence-based recommendations for safe, effective, and appropriate thyroidectomy.
BACKGROUND
Surgical management of thyroid disease has evolved considerably over several decades leading to variability in rendered care. Over 100,000 thyroid operations are performed annually in the US.
METHODS
The medical literature from 1/1/1985 to 11/9/2018 was reviewed by a panel of 19 experts in thyroid disorders representing multiple disciplines. The authors used the best available evidence to construct surgical management recommendations. Levels of evidence were determined using the American College of Physicians grading system, and management recommendations were discussed to consensus. Members of the American Association of Endocrine Surgeons reviewed and commented on preliminary drafts of the content.
RESULTS
These clinical guidelines analyze the indications for thyroidectomy as well as its definitions, technique, morbidity, and outcomes. Specific topics include Pathogenesis and Epidemiology, Initial Evaluation, Imaging, Fine Needle Aspiration Biopsy Diagnosis, Molecular Testing, Indications, Extent and Outcomes of Surgery, Preoperative Care, Initial Thyroidectomy, Perioperative Tissue Diagnosis, Nodal Dissection, Concurrent Parathyroidectomy, Hyperthyroid Conditions, Goiter, Adjuncts and Approaches to Thyroidectomy, Laryngology, Familial Thyroid Cancer, Postoperative Care and Complications, Cancer Management, and Reoperation.
CONCLUSIONS
Evidence-based guidelines were created to assist clinicians in the optimal surgical management of thyroid disease.

Identifiants

DOI: 10.1097/SLA.0000000000003580 PMID: 32079830
pubmed: 32079830
doi: 10.1097/SLA.0000000000003580
pii: 00000658-202003000-00028
doi:

Types de publication

Journal Article Practice Guideline Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e21-e93

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Sun GH, DeMonner S, Davis MM. Epidemiological and economic trends in inpatient and outpatient thyroidectomy in the United States, 1996–2006. Thyroid 2013; 23:727–733.
Rubio GA, Koru-Sengal T, Vaghaiwalla TM, Parikh PP, Farra JC, Lew JI. Postoperative outcomes in Graves’ disease patients: results from the nationwide inpatient sample database. Thyroid 2017; 27:825–831.
Haugen BRM, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26:1–133.
Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. J Endocrinol Invest 2010; 33: (5 suppl): 51–56.
Gharib H, Zeiger MA, Zini M, et al. AACE/AME Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006; 12:63–102.
Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151:959–968.
Sawka AM, Carty SE, Haugen BR, et al. American Thyroid Association Guidelines and Statements: past, present, and future. Thyroid 2018; 28:692–706.
Qaseem A, Snow V, Owens DK, et al. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med 2010; 153:194–199.
Lewis MH, Gohagan JK, Merenstein DJ. The locality rule and the physician's dilemma: local medical practices vs the national standard of care. JAMA 2007; 297:2633–2637.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388:906–918.
Chaker L, Bianco AC, Jonklaas J, et al. Hypothyroidism. Lancet 2017; 390:1550–1562.
Porterfield JR Jr, Thompson GB, Farley DR, et al. Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J Surg 2008; 32:1278–1284.
Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26:1343–1421.
Smith TJ, Hegedus L. Graves’ disease. N Engl J Med 2017; 376:185.
Berghout A, Wiersinga WM, Smits NJ, et al. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med 1990; 89:602–608.
Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365:649–651.
Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012; 97:4549–4558.
Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489–499.
Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010; 62:1312–1318.
Kakudo K, Li Y, Hirokawa M, et al. Diagnosis of Hashimoto's thyroiditis and IgG4-related sclerosing disease. Pathol Int 2011; 61:175–183.
Li Y, Bai Y, Liu Z, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto's autoimmune thyroiditis. Pathol Int 2009; 59:636–641.
Stan MN, Sonawane V, Sebo TJ, et al. Riedel's thyroiditis association with IgG4-related disease. Clin Endocrinol (Oxf) 2017; 86:425–430.
Lai X, Xia Y, Zhang B, et al. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk. Oncotarget 2017; 8:62414–62424.
Wormer BA, McHenry CR. Hashimoto's thyroiditis: outcome of surgical resection for patients with thyromegaly and compressive symptoms. Am J Surg 2011; 201:416–419.
Reiners C, Wegscheider K, Schicha H, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid 2004; 14:926–932.
Kamran SC, Marqusee E, Kim MI, et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013; 98:564–570.
Cavallo A, Johnson DN, White MG, et al. Thyroid nodule size at ultrasound as a predictor of malignancy and final pathologic size. Thyroid 2017; 27:641–650.
Hammad AY, Noureldine SI, Hu T, et al. A meta-analysis examining the independent association between thyroid nodule size and malignancy. Gland Surg 2016; 5:312–317.
McHenry CR, Huh ES, Machekano RN. Is nodule size an independent predictor of thyroid malignancy? Surgery 2008; 144:1062–1068.
Noureldine SI, Tufano RP. Association of Hashimoto's thyroiditis and thyroid cancer. Curr Opin Oncol 2015; 27:21–25.
Shin JJ, Caragacianu D, Randolph GW. Impact of thyroid nodule size on prevalence and post-test probability of malignancy: a systematic review. Laryngoscope 2015; 125:263–272.
Shrestha M, Crothers BA, Burch HB. The impact of thyroid nodule size on the risk of malignancy and accuracy of fine-needle aspiration: a 10-year study from a single institution. Thyroid 2012; 22:1251–1256.
Sippel RS, Elaraj DM, Khanafshar E, et al. Tumor size predicts malignant potential in Hurthle cell neoplasms of the thyroid. World J Surg 2008; 32:702–707.
Cibas ES, Ali SZ. The bethesda system for reporting thyroid cytopathology. Thyroid 2009; 19:1159–1165.
Mai KT, Landry DC, Thomas J, et al. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma. Histopathology 2001; 39:25–32.
Shi H, Bobanga I, McHenry CR. Are large thyroid nodules classified as benign on fine needle aspiration more likely to harbor cancer? Am J Surg 2017; 213:464–466.
Tzen CY, Huang YW, Fu YS. Is atypical follicular adenoma of the thyroid a preinvasive malignancy? Hum Pathol 2003; 34:666–669.
Lloyd RV, Osamura RY, Klöppel G, Rosai J, eds. WHO Classification of Tumours of Endocrine Organs (IARC WHO Classification of Tumours). 4th ed. Lyon, France: IARC; 2017.
Asa SL, Giordano TJ, LiVolsi VA. Implications of the TCGA genomic characterization of papillary thyroid carcinoma for thyroid pathology: does follicular variant papillary thyroid carcinoma exist? Thyroid 2015; 25:1–2.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006; 295:2164–2167.
Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140:317–322.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115:3801–3807.
Lin JS, Bowles EJA, Williams SB, et al. Screening for thyroid cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2017; 317:1888–1903.
Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 2017; 317:1338–1348.
Dionigi G, Kraimps JL, Schmid KW, et al. Minimally invasive follicular thyroid cancer (MIFTC): a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 2014; 399:165–184.
Chindris AM, Casler JD, Bernet VJ, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015; 100:55–62.
Ganly I, Makarov V, Deraje S, et al. Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell 2018; 34:256–270.
Gopal RK, Kübler K, Calvo SE, et al. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in hurthle cell carcinoma. Cancer Cell 2018; 34:242–255.
Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer 2004; 100:950–957.
Volante M, Papotti M. Poorly differentiated thyroid carcinoma: 5 years after the 2004 WHO classification of endocrine tumours. Endocr Pathol 2010; 21:1–6.
Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 2007; 31:1256–1264.
Hunt JL, Tometsko M, LiVolsi VA, et al. Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid. Am J Surg Pathol 2003; 27:1559–1564.
Xu B, Ghossein R. Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol 2016; 27:205–212.
Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012; 22:1104–1139.
Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016; 126:1052–1066.
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567–610.
Baloch ZW, LiVolsi VA. C-cells and their associated lesions and conditions: a pathologists perspective. Turk Patoloji Derg 2015; 31: (suppl 1): 60–79.
Sharma A, Jasim S, Reading CC, et al. Clinical presentation and diagnostic challenges of thyroid lymphoma: a cohort study. Thyroid 2016; 26:1061–1067.
Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985; 312:601–604.
Rossi D. Thyroid lymphoma: beyond antigen stimulation. Leuk Res 2009; 33:607–609.
Matsuzuka F, Miyauchi A, Katayama S, et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993; 3:93–99.
Schneider AB, Ron E, Lubin J, et al. Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 1993; 77:362–369.
Ron E. Cancer risks from medical radiation. Health Phys 2003; 85:47–59.
Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab 2017; 61:180–187.
Nikiforov YE. Radiation-induced thyroid cancer: what we have learned from Chernobyl. Endocr Pathol 2006; 17:307–317.
Tronko MD, Howe GR, Bogdanova TI, et al. A cohort study of thyroid cancer and other thyroid diseases after the chornobyl accident: thyroid cancer in Ukraine detected during first screening. J Natl Cancer Inst 2006; 98:897–903.
Ohira T, Takahashi H, Yasumura S, et al. Comparison of childhood thyroid cancer prevalence among 3 areas based on external radiation dose after the Fukushima Daiichi nuclear power plant accident: The Fukushima health management survey. Medicine (Baltimore) 2016; 95:e4472.
Ohira T, Takahashi H, Yasumura S, et al. Associations between childhood thyroid cancer and external radiation dose after the Fukushima Daiichi Nuclear Power Plant Accident. Epidemiology 2018; 29:e32–e34.
Levin RJ, De Simone NF, Slotkin JF, et al. Incidence of thyroid cancer surrounding Three Mile Island nuclear facility: the 30-year follow-up. Laryngoscope 2013; 123:2064–2071.
Sinnott B, Ron E, Schneider AB. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr Rev 2010; 31:756–773.
de Vathaire F, Haddy N, Allodji RS, et al. Thyroid radiation dose and other risk factors of thyroid carcinoma following childhood cancer. J Clin Endocrinol Metab 2015; 100:4282–4290.
Bhatti P, Veiga LH, Ronckers CM, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010; 174:741–752.
Veiga LH, Holmberg E, Anderson H, et al. Thyroid cancer after childhood exposure to external radiation: an updated pooled analysis of 12 studies. Radiat Res 2016; 185:473–484.
Grantzau T, Overgaard J. Risk of second non-breast cancer among patients treated with and without postoperative radiotherapy for primary breast cancer: a systematic review and meta-analysis of population-based studies including 522,739 patients. Radiother Oncol 2016; 121:402–413.
Metzger R, Milas M. Inherited cancer syndromes and the thyroid: an update. Curr Opin Oncol 2014; 26:51–61.
Milas M, Mester J, Metzger R, et al. Should patients with Cowden syndrome undergo prophylactic thyroidectomy? Surgery 2012; 152:1201–1210.
Brauckhoff M, Machens A, Lorenz K, et al. Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective. Ann Surg 2014; 259:800–806.
Straccia P, Mosseri C, Brunelli C, et al. Diagnosis and treatment of metastases to the thyroid gland: a meta-analysis. Endocr Pathol 2017; 28:112–120.
Romero Arenas MA, Ryu H, Lee S, et al. The role of thyroidectomy in metastatic disease to the thyroid gland. Ann Surg Oncol 2014; 21:434–439.
Chen AY, Bernet VJ, Carty SE, et al. American Thyroid Association statement on optimal surgical management of goiter. Thyroid 2014; 24:181–189.
Vansant MB, Kunduk M, McWhorter AJ. A review of postsurgical dysphagia in nonmalignant disease. Curr Opin Otolaryngol Head Neck Surg 2016; 24:477–482.
Holler T, Anderson J. Prevalence of voice & swallowing complaints in Pre-operative thyroidectomy patients: a prospective cohort study. J Otolaryngol Head Neck Surg 2014; 43:28.
Greenblatt DY, Sippel R, Leverson G, et al. Thyroid resection improves perception of swallowing function in patients with thyroid disease. World J Surg 2009; 33:255–260.
Burns P, Timon C. Thyroid pathology and the globus symptom: are they related? A two year prospective trial. J Laryngol Otol 2007; 121:242–245.
Nam IC, Choi H, Kim ES, et al. Characteristics of thyroid nodules causing globus symptoms. Eur Arch Otorhinolaryngol 2015; 272:1181–1188.
Shen WT, Kebebew E, Duh QY, et al. Predictors of airway complications after thyroidectomy for substernal goiter. Arch Surg 2004; 139:656–659.
Stang MT, Armstrong MJ, Ogilvie JB, et al. Positional dyspnea and tracheal compression as indications for goiter resection. Arch Surg 2012; 147:621–626.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 2014; 24:1670–1751.
Caulley L, Johnson-Obaseki S, Luo L, Javidnia H. Risk factors for postoperative complications in total thyroidectomy: a retrospective, risk-adjusted analysis from the National Surgical Quality Improvement Program. Medicine (Baltimore) 2017; 96:e5752.
Abraham CR, Ata A, Carsello CB, Chan TL, Stain SC, Beyer TD. A NSQIP risk assessment for thyroid surgery based on comorbidities. J Am Coll Surg 2014; 218:1231–1237.
Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes Rev 2015; 16:1042–1054.
Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies. Thyroid 2016; 26:306–318.
Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med 1995; 155:2418–2423.
De Filippis EA, Sabet A, Sun MR, Garber JR. Pemberton's sign: explained nearly 70 years later. J Clin Endocrinol Metab 2014; 99:1949–1954.
Chandrasekhar SS, Randolph GW, Seidman MD, et al. Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngol Head Neck Surg 2013; 148: (6 suppl): S1–S37.
Zanocco K, Kaltman DJ, Wu JX, et al. Cost effectiveness of routine laryngoscopy in the surgical treatment of differentiated thyroid cancer. Ann Surg Oncol 2018; 25:949–956.
Choong KC, McHenry CR. Thyroid cancer in patients with toxic nodular goiter: is the incidence increasing? Am J Surg 2015; 209:974–976.
Smith JJ, Chen X, Schneider DF, et al. Toxic nodular goiter and cancer: a compelling case for thyroidectomy. Ann Surg Oncol 2013; 20:1336–1340.
Morita SY, Somervell H, Umbricht CB, et al. Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Surgery 2008; 144:862–866.
Murray SE, Sippel RS, Chen H. Incidence of concomitant hyperparathyroidism in patients with thyroid disease requiring surgery. J Surg Res 2012; 178:264–267.
Jovanovic MD, Zivaljevic VR, Diklic AD, Rovcanin BR, V Zoric G, Paunovic IR. Surgical treatment of concomitant thyroid and parathyroid disorders: analysis of 4882 cases. Eur Arch Otorhinolaryngol 2017; 274:997–1004.
Prinz RA, Paloyan E, Lawrence AM, Barbato AL, Braithwaite SS, Brooks MH. Unexpected parathyroid disease discovered at thyroidectomy in irradiated patients. Am J Surg 1981; 142:355–357.
Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163–168.
Costante G, Durante C, Francis Z, et al. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009; 5:35–44.
Network, N.C.C. Thyroid Carcinoma (Version 2.2015). http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed July 19, 2019
Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2655–2663.
Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029–2034.
Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid 2015; 25:3–14.
Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003; 134:946–954.
Kwak JY. Thyroid ultrasonography for personalized approach at thyroid nodules. Endocrine 2016; 52:181–182.
Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260:892–899.
Moon HG, Jung EJ, Park ST, et al. Role of ultrasonography in predicting malignancy in patients with thyroid nodules. World J Surg 2007; 31:1410–1416.
Moon HJ, Kim EK, Kwak JY. Malignancy risk stratification in thyroid nodules with benign results on cytology: combination of thyroid imaging reporting and data system and Bethesda system. Ann Surg Oncol 2014; 21:1898–1903.
Salmaslioglu A, Erbil Y, Dural C, et al. Predictive value of sonographic features in preoperative evaluation of malignant thyroid nodules in a multinodular goiter. World J Surg 2008; 32:1948–1954.
Moon HJ, Kwak JY, Kim MJ, et al. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology 2010; 255:260–269.
Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87:1941–1946.
Gul K, Ersoy R, Dirikoc A, et al. Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings. Endocrine 2009; 36:464–472.
Cappelli C, Pirola I, Cumetti D, et al. Is the anteroposterior and transverse diameter ratio of nonpalpable thyroid nodules a sonographic criteria for recommending fine-needle aspiration cytology? Clin Endocrinol (Oxf) 2005; 63:689–693.
Tang AL, Falciglia M, Yang H, et al. Validation of American Thyroid Association ultrasound risk assessment of thyroid nodules selected for ultrasound fine-needle aspiration. Thyroid 2017; 27:1077–1082.
Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab 2009; 94:1748–1751.
Tae HJ, Lim DJ, Baek KH, et al. Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid 2007; 17:461–466.
Ito Y, Amino N, Yokozawa T, et al. Ultrasonographic evaluation of thyroid nodules in 900 patients: comparison among ultrasonographic, cytological, and histological findings. Thyroid 2007; 17:1269–1276.
Moon WJ, Baek JH, Jung SL, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 2011; 12:1–14.
Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. Radiology 2008; 247:762–770.
Brito JP, Gionfriddo MR, Al Nofal A, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab 2014; 99:1253–1263.
Kim DS, Kim JH, Na DG, et al. Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas. J Ultrasound Med 2009; 28:1685–1692.
Yang GC, Fried KO. Most thyroid cancers detected by sonography lack intranodular vascularity on color doppler imaging: review of the literature and sonographic-pathologic correlations for 698 thyroid neoplasms. J Ultrasound Med 2017; 36:89–94.
Jeh SK, Jung SL, Kim BS, Lee YS. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol 2007; 8:192–197.
Iared W, Shigueoka DC, Cristófoli JC, et al. Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis. J Ultrasound Med 2010; 29:419–425.
Khadra H, Bakeer M, Hauch A, Hu T, Kandil E. Is vascular flow a predictor of malignant thyroid nodules? A meta-analysis. Gland Surg 2016; 5:576–582.
Grant EG, Tessler FN, Hoang JK, et al. Thyroid ultrasound reporting lexicon: white paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. J Am Coll Radiol 2015; 12 (12 pt A):1272–1279.
Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017; 14:587–595.
Choi YJ, Baek JH, Baek SH, et al. Web-based malignancy risk estimation for thyroid nodules using ultrasonography characteristics: development and validation of a predictive model. Thyroid 2015; 25:1306–1312.
Zhang J, Liu BJ, Xu HX, et al. Prospective validation of an ultrasound-based thyroid imaging reporting and data system (TI-RADS) on 3980 thyroid nodules. Int J Clin Exp Med 2015; 8:5911–5917.
Kwak JY, Kim EK, Moon HJ, et al. Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid 2009; 19:743–748.
Ghervan C, Silaghi A, Nemes C. Parathyroid incidentaloma detected during thyroid sonography—prevalence and significance beyond images. Med Ultrason 2012; 14:187–191.
Cho M, Oweity T, Brandler TC, Fried K, Levine P. Distinguishing parathyroid and thyroid lesions on ultrasound-guided fine-needle aspiration: a correlation of clinical data, ancillary studies, and molecular analysis. Cancer Cytopathol 2017; 125:674–682.
Langer JE, Mandel SJ. Sonographic imaging of cervical lymph nodes in patients with thyroid cancer. Neuroimaging Clin N Am 2008; 18:479–489.
Leboulleux S, Girard E, Rose M, et al. Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92:3590–3594.
Ito Y, Higashiyama T, Takamura Y, et al. Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection. World J Surg 2007; 31:2085–2091.
Choi JS, Kim J, Kwak JY, Kim MJ, Chang HS, Kim EK. Preoperative staging of papillary thyroid carcinoma: comparison of ultrasound imaging and CT. AJR Am J Roentgenol 2009; 193:871–878.
Hwang HS, Orloff LA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. Laryngoscope 2011; 121:487–491.
Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol 2001; 11:2411–2424.
Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery 2011; 150:1048–1057.
Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg 1998; 85:252–254.
Wu G, Fraser S, Pai SI, Farrag TY, Ladenson PW, Tufano RP. Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid reoperation after previous total thyroidectomy and radioactive iodine for papillary thyroid cancer. Head Neck 2012; 34:1418–1421.
Farrag T, Lin F, Brownlee N, Kim M, Sheth S, Tufano RP. Is routine dissection of level II-B and V-A necessary in patients with papillary thyroid cancer undergoing lateral neck dissection for FNA-confirmed metastases in other levels. World J Surg 2009; 33:1680–1683.
Kuna SK, Bracic I, Tesic V, Kuna K, Herceg GH, Dodig D. Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. J Ultrasound Med 2006; 25:1531–1537.
Görges R, Eising EG, Fotescu D, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003; 16:191–206.
Sipos JA. Advances in ultrasound for the diagnosis and management of thyroid cancer. Thyroid 2009; 19:1363–1372.
Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol 2002; 178:693–697.
Ahuja AT, King W, Metreweli C. Role of ultrasonography in thyroid metastases. Clin Radiol 1994; 49:627–629.
Ahuja AT, Ying M, Ho SS, Metreweli C. Distribution of intranodal vessels in differentiating benign from metastatic neck nodes. Clin Radiol 2001; 56:197–201.
American Thyroid Association Surgery Working Group, American Association of Endocrine Surgeons, American Academy of Otolaryngology-Head and Neck Surgery, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid 2009; 19:1153–1158.
Al-azawi D, Mann GB, Judson RT, Miller JA. Endocrine surgeon-performed US guided thyroid FNAC is accurate and efficient. World J Surg 2012; 36:1947–1952.
Kumbhar SS, O’Malley RB, Robinson TJ, et al. Why thyroid surgeons are frustrated with radiologists: lessons learned from pre- and postoperative US. Radiographics 2016; 36:2141–2153.
Monteiro R, Han A, Etiwy M, et al. Importance of surgeon-performed ultrasound in the preoperative nodal assessment of patients with potential thyroid malignancy. Surgery 2018; 163:112–117.
Wong KP, Au KP, Lam S, Lang BH. Lessons learned after 1000 cases of transcutaneous laryngeal ultrasound (TLUSG) with laryngoscopic validation: is there a role of TLUSG in patients indicated for laryngoscopic examination before thyroidectomy? Thyroid 2017; 27:88–94.
Kandil E, Deniwar A, Noureldine SI, et al. Assessment of vocal fold function using transcutaneous laryngeal ultrasonography and flexible laryngoscopy. JAMA Otolaryngol Head Neck Surg 2016; 142:74–78.
Parangi S. Editorial: Translaryngeal vocal cord ultrasound: Ready for prime time. Surgery 2016; 159:67–69.
Carneiro-Pla D, Miller BS, Wilhelm SM, et al. Feasibility of surgeon-performed transcutaneous vocal cord ultrasonography in identifying vocal cord mobility: a multi-institutional experience. Surgery 2014; 156:1597–1602.
Carneiro-Pla D, Solorzano CC, Wilhelm SM. Impact of vocal cord ultrasonography on endocrine surgery practices. Surgery 2016; 159:58–64.
Moon HJ, Kim EK, Yoon JH, Kwak JY. Differences in the diagnostic performances of staging US for thyroid malignancy according to experience. Ultrasound Med Biol 2012; 38:568–573.
Bhatki AM, Brewer B, Robinson-Smith T, Nikiforov Y, Steward DL. Adequacy of surgeon-performed ultrasound-guided thyroid fine-needle aspiration biopsy. Otolaryngol Head Neck Surg 2008; 139:27–31.
Jeong HS, Baek CH, Son YI, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 2006; 65:402–407.
Padovani RP, Kasamatsu TS, Nakabashi CCD, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. Thyroid 2012; 22:926–930.
Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 2007; 92:2917–2922.
Moon HJ, Sung JM, Kim EK, Yoon JH, Youk JH, Kwak JY. Diagnostic performance of gray-scale US and elastography in solid thyroid nodules. Radiology 2012; 262:1002–1013.
Azizi G, Keller J, Lewis M, Puett D, Rivenbark K, Malchoff C. Performance of elastography for the evaluation of thyroid nodules: a prospective study. Thyroid 2013; 23:734–740.
Are C, Hsu JF, Schoder H, et al. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol 2007; 14:239–247.
Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008; 207:259–264.
Barrio M, Czernin J, Yeh MW, et al. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun 2016; 37:1290–1296.
Hari Kumar KV, Pasupuleti V, Jayaraman M, Abhyuday V, Rayudu BR, Modi KD. Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr Pract 2009; 15:6–9.
Rosario PW, Santos JB, Nunes NS, da Silva AL, Calsolari MR. Color flow Doppler sonography for the etiologic diagnosis of thyrotoxicosis. Horm Metab Res 2014; 46:505–509.
Avram AM. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med Technol 2014; 42:170–180.
Grünwald F, Kälicke T, Feine U, Lietzenmayer R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999; 26:1547–1552.
Francis CL, Nalley C, Fan C, Bodenner D, Stack BC Jr. 18F-fluorodeoxyglucose and 131I radioguided surgical management of thyroid cancer. Otolaryngol Head Neck Surg 2012; 146:26–32.
Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001; 42:71–76.
Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999; 84:2291–2302.
Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006; 91:498–505.
Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer. Ann Surg Oncol 2008; 15:286–292.
Kim SJ, Lee TH, Kim IJ, Kim YK. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin. Eur J Radiol 2009; 70:17–24.
Mirallié E, Guillan T, Bridji B, et al. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 2007; 142:952–958.
Shammas A, Degirmenci B, Mountz JM, et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007; 48:221–226.
Robbins RJ, Srivastava S, Shaha A, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:6010–6016.
Agrawal A, Hall NC, Ringel MD, Povoski SP, Martin EW Jr. Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma. Laryngoscope 2008; 118:2190–2194.
Leboulleux S, Schroeder PR, Busaidy NL, et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009; 94:1310–1316.
Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 1979; 241:481–484.
Wetzig NR, Giddings AE. Solitary thyroid nodule: audit shows improved care requires cytological diagnosis. Ann R Coll Surg Engl 1989; 71:316–319.
Sosa JA, Hanna JW, Robinson KA, Lanman RB. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 2013; 154:1420–1426.
Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer 2005; 103:2269–2273.
Cavallo A, Johnson DN, White MG, et al. Thyroid nodule size at ultrasound as a predictor of malignancy and final pathologic size. Thyroid 2017; 27:641–650.
Cappelli C, Pirola I, Agosti B, et al. Complications after fine-needle aspiration cytology: a retrospective study of 7449 consecutive thyroid nodules. Br J Oral Maxillofac Surg 2017; 55:266–269.
Abu-Yousef MM, Larson JH, Kuehn DM, Wu AS, Laroia AT. Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications. Ultrasound Q 2011; 27:157–159.
Lyle MA, Dean DS. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients taking novel oral anticoagulants. Thyroid 2015; 25:373–376.
Pitman MB, Abele J, Ali SZ, et al. Techniques for thyroid FNA: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:407–424.
Guo HQ, Zhang ZH, Zhao H, Niu LJ, Chang Q, Pan QJ. Factors influencing the reliability of thyroid fine-needle aspiration: analysis of thyroid nodule size, guidance mode for aspiration and preparation method. Acta Cytol 2015; 59:169–174.
Izquierdo R, Arekat MR, Knudson PE, et al. Comparison of palpation-guided versus ultrasound-guided fine-needle aspiration biopsies of thyroid nodules in an outpatient endocrinology practice. Endocr Pract 2006; 12:609–614.
Can AS, Peker K. Comparison of palpation-versus ultrasound-guided fine-needle aspiration biopsies in the evaluation of thyroid nodules. BMC Res Notes 2008; 1:12.
Can AS. Cost-effectiveness comparison between palpation- and ultrasound-guided thyroid fine-needle aspiration biopsies. BMC Endocr Disord 2009; 9:14.
Cibas ES, Alexander EK, Benson CB, et al. Indications for thyroid FNA and pre-FNA requirements: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:390–399.
Lee YH, Baek JH, Jung SL, et al. Ultrasound-guided fine needle aspiration of thyroid nodules: a consensus statement by the Korean society of thyroid radiology. Korean J Radiol 2015; 16:391–401.
Lalzad A, Ristitsch D, Downey W, Little AF, Schneider-Kolsky ME. Effect of ultrasound transmission gel on ultrasound-guided fine needle aspiration cytological specimens of thyroid. Cytopathology 2012; 23:330–333.
Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab 2014; 99:1970–1982.
Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006; 91:1364–1369.
Shin JH, Baek JH, Chung J, et al. Ultrasonography diagnosis and imaging-based management of thyroid nodules: revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations. Korean J Radiol 2016; 17:370–395.
Witt BL, Schmidt RL. Rapid onsite evaluation improves the adequacy of fine-needle aspiration for thyroid lesions: a systematic review and meta-analysis. Thyroid 2013; 23:428–435.
Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008; 5:6.
de Koster EJ, Kist JW, Vriens MR, Borel Rinkes IH, Valk GD, de Keizer B. Thyroid ultrasound-guided fine-needle aspiration: the positive influence of on-site adequacy assessment and number of needle passes on diagnostic cytology rate. Acta Cytol 2016; 60:39–45.
Cristo AP, Goldstein HF, Faccin CS, Maia AL, Graudenz MS. Increasing diagnostic effectiveness of thyroid nodule evaluation by implementation of cell block preparation in routine US-FNA analysis. Arch Endocrinol Metab 2016; 60:367–373.
Grani G, Calvanese A, Carbotta G, et al. Intrinsic factors affecting adequacy of thyroid nodule fine-needle aspiration cytology. Clin Endocrinol (Oxf) 2013; 78:141–144.
Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36:425–437.
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017; 27:1341–1346.
Faquin WC, Wong LQ, Afrogheh AH, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol 2016; 124:181–187.
Strickland KC, Howitt BE, Marqusee E, et al. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid 2015; 25:987–992.
Baloch ZW, Seethala RR, Faquin WC, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): a changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathol 2016; 124:616–620.
Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol 2012; 56:333–339.
McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH. The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. Surgery 2007; 142:837–844.
Wharry LI, McCoy KL, Stang MT, et al. Thyroid nodules (>/ = 4 cm): can ultrasound and cytology reliably exclude cancer? World J Surg 2014; 38:614–621.
Albuja-Cruz MB, Goldfarb M, Gondek SS, Allan BJ, Lew JI. Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. J Surg Res 2013; 181:6–10.
Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol 2014; 21:26–35.
Manning AM, Yang H, Falciglia M, Mark JR, Steward DL. Thyroid ultrasound-guided fine-needle aspiration cytology results: observed increase in indeterminate rate over the past decade. Otolaryngol Head Neck Surg 2017; 156:611–615.
Chen JC, Pace SC, Chen BA, Khiyami A, McHenry CR. Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology. Surgery 2012; 152:1037–1044.
Gweon HM, Son EJ, Youk JH, Kim JA. Thyroid nodules with Bethesda system III cytology: can ultrasonography guide the next step? Ann Surg Oncol 2013; 20:3083–3088.
Méndez W, Rodgers SE, Lew JI, Montano R, Solórzano CC. Role of surgeon-performed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules. Ann Surg Oncol 2008; 15:2487–2492.
Gan TR, Nga ME, Lum JH, et al. Thyroid cytology-nuclear versus architectural atypia within the “Atypia of undetermined significance/follicular lesion of undetermined significance” Bethesda category have significantly different rates of malignancy. Cancer 2017; 125:245–256.
Chen JC, Chen JC, Pace SC, Khiyami A, McHenry CR. Should atypia of undetermined significance be subclassified to better estimate risk of thyroid cancer? Am J Surg 2014; 207:331–336.
Zhang W, Policarpio-Nicolas ML. Aspiration cytology of primary thyroid paraganglioma. Diagn Cytopathol 2015; 43:838–843.
Cibas ES, Baloch ZW, Fellegara G, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med 2013; 159:325–332.
Gerhard R, Boerner SL. The value of second opinion in thyroid cytology: a review. Cancer Cytopathol 2014; 122:611–619.
Olson MT, Boonyaarunnate T, Aragon Han P, Umbricht CB, Ali SZ, Zeiger MA. A tertiary center's experience with second review of 3885 thyroid cytopathology specimens. J Clin Endocrinol Metab 2013; 98:1450–1457.
Trimboli P, Treglia G, Guidobaldi L, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 2015; 82:280–285.
Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf) 2014; 80:135–140.
Liu X, Medici M, Kwong N, et al. Bethesda categorization of thyroid nodule cytology and prediction of thyroid cancer type and prognosis. Thyroid 2016; 26:256–261.
Rago T, Scutari M, Latrofa F, et al. The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease. J Clin Endocrinol Metab 2014; 99:3700–3707.
Kleiman DA, Beninato T, Soni A, Shou Y, Zarnegar R, Fahey TJ 3rd. Does bethesda category predict aggressive features in malignant thyroid nodules? Ann Surg Oncol 2013; 20:3484–3490.
Nishino M, Nikiforova M. Update on molecular testing for cytologically indeterminate thyroid nodules. Arch Pathol Lab Med 2018; 142:446–457.
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159:676–690.
National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2017). http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed July 19, 2019.
Aragon Han P, Olson MT, Fazeli R, et al. The impact of molecular testing on the surgical management of patients with thyroid nodules. Ann Surg Oncol 2014; 21:1862–1869.
U.S. Department of Health and Human Services. ACCE Model Process for Evaluating Genetic Tests. https://www.cdc.gov/genomics/gtesting/ACCE/. Accessed July 19, 2019.
Ferris RL, Baloch Z, Bernet V, et al. American thyroid association statement on surgical application of molecular profiling for thyroid nodules: current impact on perioperative decision making. Thyroid 2015; 25:760–768.
Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009; 94:2092–2098.
Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95:1365–1369.
Yip L, Farris C, Kabaker AS, et al. Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies. J Clin Endocrinol Metab 2012; 97:1905–1912.
Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96:3390–3397.
Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. Thyroid 2014; 24:1479–1487.
Eszlinger M, Hegedus L, Paschke R. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2014; 28:545–557.
Eszlinger M, Krogdahl A, Münz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid 2014; 24:305–313.
Krane JF, Cibas ES, Alexander EK, Paschke R, Eszlinger M. Molecular analysis of residual ThinPrep material from thyroid FNAs increases diagnostic sensitivity. Cancer Cytopathol 2015; 123:356–361.
Eszlinger M, Böhme K, Ullmann M, et al. Evaluation of a two-year routine application of molecular testing of thyroid fine-needle aspirations using a seven-gene panel in a primary referral setting in Germany. Thyroid 2017; 27:402–411.
Yip L, Wharry LI, Armstrong MJ, et al. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg 2014; 260:163–168.
Labourier E, Shifrin A, Busseniers AE, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab 2015; 100:2743–2750.
Valderrabano P, Leon ME, Centeno BA, et al. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol 2016; 174:621–629.
Partyka KL, Randolph ML, Lawrence KA, Cramer H, Wu HH. Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: a comparison of two proprietary testing platforms. Diagn Cytopathol 2018; 46:320–325.
Nikiforova MN, Mercurio S, Wald AI, et al. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules. Cancer 2018; 124:1682–1690.
Valderrabano P, Khazai L, Leon ME, et al. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology. Endocr Relat Cancer 2017; 24:127–136.
Taye A, Gurciullo D, Miles BA, et al. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules. Surgery 2018; 163:97–103.
Nikiforov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer 2014; 120:3627–3634.
Steward DL, Carty SE, Sippel RS, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study. JAMA Oncol 2019; 5:204–212.
Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010; 95:5296–5304.
Kloos RT, Reynolds JD, Walsh PS, et al. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules? J Clin Endocrinol Metab 2013; 98:E761–E768.
Pankratz DG, Hu Z, Kim SY, et al. Analytical performance of a gene expression classifier for medullary thyroid carcinoma. Thyroid 2016; 26:1573–1580.
Patel KN, Angell TE, Babiarz J, et al. Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules. JAMA Surg 2018; 153:817–824.
Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012; 367:705–715.
McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2014; 99:4069–4077.
Chaudhary S, Hou Y, Shen R, Hooda S, Li Z. Impact of the Afirma gene expression classifier result on the surgical management of thyroid nodules with category III/IV cytology and its correlation with surgical outcome. Acta Cytol 2016; 60:205–210.
Wu JX, Young S, Hung ML, et al. Clinical factors influencing the performance of gene expression classifier testing in indeterminate thyroid nodules. Thyroid 2016; 26:916–922.
Samulski TD, LiVolsi VA, Wong LQ, Baloch Z. Usage trends and performance characteristics of a “gene expression classifier” in the management of thyroid nodules: an institutional experience. Diagn Cytopathol 2016; 44:867–873.
Al-Qurayshi Z, Deniwar A, Thethi T, et al. Association of malignancy prevalence with test properties and performance of the gene expression classifier in indeterminate thyroid nodules. JAMA Otolaryngol Head Neck Surg 2017; 143:403–408.
Noureldine SI, Olson MT, Agrawal N, Prescott JD, Zeiger MA, Tufano RP. Effect of gene expression classifier molecular testing on the surgical decision-making process for patients with thyroid nodules. JAMA Otolaryngol Head Neck Surg 2015; 141:1082–1088.
Harrell RM, Bimston DN. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocr Pract 2014; 20:364–369.
Duh QY, Busaidy NL, Rahilly-Tierney C, Gharib H, Randolph G. A systematic review of the methods of diagnostic accuracy studies of the Afirma Gene Expression Classifier. Thyroid 2017; 27:1215–1222.
Celik B, Whetsell CR, Nassar A. Afirma GEC and thyroid lesions: an institutional experience. Diagn Cytopathol 2015; 43:966–970.
Dhingra JK. Office-based ultrasound-guided FNA with molecular testing for thyroid nodules. Otolaryngol Head Neck Surg 2016; 155:564–567.
Marti JL, Avadhani V, Donatelli LA, et al. Wide inter-institutional variation in performance of a molecular classifier for indeterminate thyroid nodules. Ann Surg Oncol 2015; 22:3996–4001.
Roychoudhury S, Klein M, Souza F, et al. How “suspicious” is that nodule? Review of “suspicious” Afirma gene expression classifier in high risk thyroid nodules. Diagn Cytopathol 2017; 45:308–311.
Baca SC, Wong KS, Strickland KC, et al. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes. Cancer Cytopathol 2017; 125:313–322.
Harrison G, Sosa JA, Jiang X. Evaluation of the Afirma gene expression classifier in repeat indeterminate thyroid nodules. Arch Pathol Lab Med 2017; 141:985–989.
Kay-Rivest E, Tibbo J, Bouhabel S, et al. The first Canadian experience with the Afirma(R) gene expression classifier test. J Otolaryngol Head Neck Surg 2017; 46:25.
Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2011; 96:E1719–E1726.
Duick DS, Klopper JP, Diggans JC, et al. The impact of benign gene expression classifier test results on the endocrinologist-patient decision to operate on patients with thyroid nodules with indeterminate fine-needle aspiration cytopathology. Thyroid 2012; 22:996–1001.
Lee L, How J, Tabah RJ, Mitmaker EJ. Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology. J Clin Endocrinol Metab 2014; 99:2674–2682.
Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery 2016; 159:118–126.
Dedhia PH, Rubio GA, Cohen MS, Miller BS, Gauger PG, Hughes DT. Potential effects of molecular testing of indeterminate thyroid nodule fine needle aspiration biopsy on thyroidectomy volume. World J Surg 2014; 38:634–638.
Sipos JA, Blevins TC, Shea HC, et al. Long-term nonoperative rate of thyroid nodules with benign results on the afirma gene expression classifier. Endocr Pract 2016; 22:666–672.
Ganly I, Ricarte Filho J, Eng S, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab 2013; 98:E962–E972.
Brauner E, Holmes BJ, Krane JF, et al. Performance of the afirma gene expression classifier in hurthle cell thyroid nodules differs from other indeterminate thyroid nodules. Thyroid 2015; 25:789–796.
Noureldine SI, Najafian A, Aragon Han P, et al. Evaluation of the effect of diagnostic molecular testing on the surgical decision-making process for patients with thyroid nodules. JAMA Otolaryngol Head Neck Surg 2016; 142:676–682.
Livhits MJ, Kuo EJ, Leung AM, et al. Gene expression classifier versus targeted next-generation sequencing in the management of indeterminate thyroid nodules. J Clin Endocrinol Metab 2018; 103:2261–2268.
Yip L, Nikiforova MN, Yoo JY, et al. Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. Ann Surg 2015; 262:519–525.
Howell GM, Nikiforova MN, Carty SE, et al. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20:47–52.
Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012; 97:4559–4570.
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015; 33:42–50.
Chen Y, Sadow PM, Suh H, et al. BRAF(V600E) is correlated with recurrence of papillary thyroid microcarcinoma: a systematic review, multi-institutional primary data analysis, and meta-analysis. Thyroid 2016; 26:248–255.
Huang Y, Qu S, Zhu G, et al. BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment. J Natl Cancer Inst 2018; 110:362–370.
Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013; 309:1493–1501.
Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 2012; 91:274–286.
Afkhami M, Karunamurthy A, Chiosea S, et al. Histopathologic and clinical characterization of thyroid tumors carrying the BRAF(K601E) Mutation. Thyroid 2016; 26:242–247.
Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014; 99:E1130–E1136.
Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab 2014; 99:E754–E765.
Kim TH, Ki CS, Kim HS, et al. Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations. J Clin Endocrinol Metab 2017; 102:1757–1764.
Shrestha RT, Karunamurthy A, Amin K, et al. Multiple mutations detected preoperatively may predict aggressive behavior of papillary thyroid cancer and guide management: a case report. Thyroid 2015; 25:1375–1378.
Moon S, Song YS, Kim YA, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 2017; 27:651–660.
Patel SG, Carty SE, McCoy KL, et al. Preoperative detection of RAS mutation may guide extent of thyroidectomy. Surgery 2017; 161:168–175.
Kim M, Jeon MJ, Oh HS, et al. BRAF and RAS mutational status in non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive subtype of encapsulated follicular variant of papillary thyroid carcinoma in Korea. Thyroid 2018; 28:504–510.
Elsheikh TM, Asa SL, Chan JK, et al. Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 2008; 130:736–744.
Balentine CJ, Vanness DJ, Schneider DF. Cost-effectiveness of lobectomy versus genetic testing (Afirma(R)) for indeterminate thyroid nodules: considering the costs of surveillance. Surgery 2018; 163:88–96.
Rivas AM, Nassar A, Zhang J, et al. ThyroSeq((R))V2.0 molecular testing: a cost-effective approach for the evaluation of indeterminate thyroid nodules. Endocr Pract 2018; 24:780–788.
Vargas-Salas S, Martínez JR, Urra S, et al. Genetic testing for indeterminate thyroid cytology: review and meta-analysis. Endocr Relat Cancer 2018; 25:R163–R177.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2016; 2:1023–1029.
Jug RC, Datto MB, Jiang XS. Molecular testing for indeterminate thyroid nodules: performance of the Afirma gene expression classifier and ThyroSeq panel. Cancer Cytopathol 2018; 126:471–480.
Eng OS, Potdevin L, Davidov T, et al. Does nodule size predict compressive symptoms in patients with thyroid nodules? Gland Surg 2014; 3:232–236.
Bakkar S, Poma AM, Corsini C, et al. Underestimated risk of cancer in solitary thyroid nodules >/=3 cm reported as benign. Langenbecks Arch Surg 2017; 402:1089–1094.
Tee YY, Lowe AJ, Brand CA, Judson RT. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg 2007; 246:714–720.
Shaha AR, Burnett C, Alfonso A, Jaffe BM. Goiters and airway problems. Am J Surg 1989; 158:378–380.
Hedayati N, McHenry CR. The clinical presentation and operative management of nodular and diffuse substernal thyroid disease. Am Surg 2002; 68:245–251.
McManus C, Luo J, Sippel R, Chen H. Should patients with symptomatic Hashimoto's thyroiditis pursue surgery? J Surg Res 2011; 170:52–55.
Mittendorf EA, McHenry CR. Thyroidectomy for selected patients with thyrotoxicosis. Arch Otolaryngol Head Neck Surg 2001; 127:61–65.
O’Brien T, Gharib H, Suman VJ, van Heerden JA. Treatment of toxic solitary thyroid nodules: surgery versus radioactive iodine. Surgery 1992; 112:1166–1170.
Hay ID. Management of patients with low-risk papillary thyroid carcinoma. Endocr Pract 2007; 13:521–533.
Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007; 13:498–512.
Pavlidis ET, Pavlidis TE. A review of primary thyroid lymphoma: molecular factors, diagnosis and management. J Invest Surg 2017. 1–6.
Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 2017; 13:644–660.
Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014; 38:68–79.
Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 2010; 136:1055–1061.
Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery 2012; 151:571–579.
Gartland RM, Lubitz CC. Impact of extent of surgery on tumor recurrence and survival for papillary thyroid cancer patients. Ann Surg Oncol 2018; 25:2520–2525.
Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg 2014; 260:601–605.
Rajjoub SR, Yan H, Calcatera NA, et al. Thyroid lobectomy is not sufficient for T2 papillary thyroid cancers. Surgery 2018; 163:1134–1143.
Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007; 246:375–381.
Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012. J Clin Endocrinol Metab 2015; 100:3270–3279.
Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998; 124:958–964.
Kim MJ, Lee MC, Lee GH, et al. Extent of surgery did not affect recurrence during 7-years follow-up in papillary thyroid cancer sized 1–4 cm: Preliminary results. Clin Endocrinol (Oxf) 2017; 87:80–86.
Guo K, Wang Z. Risk factors influencing the recurrence of papillary thyroid carcinoma: a systematic review and meta-analysis. Int J Clin Exp Pathol 2014; 7:5393–5403.
Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of high-risk characteristics requiring total thyroidectomy for 1–4 cm well-differentiated thyroid cancer. Thyroid 2016; 26:820–824.
Hirshoren N, Kaganov K, Weinberger JM, et al. Thyroidectomy practice after implementation of the 2015 American Thyroid Association Guidelines on Surgical options for patients with well-differentiated thyroid carcinoma. JAMA Otolaryngol Head Neck Surg 2018; 144:427–432.
Abu-Ghanem S, Cohen O, Raz Yarkoni T, Fliss DM, Yehuda M. Intraoperative frozen section in “suspicious for papillary thyroid carcinoma” after adoption of the bethesda system. Otolaryngol Head Neck Surg 2016; 155:779–786.
Nagarkatti SS, Faquin WC, Lubitz CC, et al. Management of thyroid nodules with atypical cytology on fine-needle aspiration biopsy. Ann Surg Oncol 2013; 20:60–65.
Cohen O, et al. Selection of atypia/follicular lesion of unknown significance patients for surgery versus active surveillance, without using genetic testing: a single institute experience, prospective analysis, and recommendations. Thyroid 2017; 27:928–935.
Coorough N, Hudak K, Jaume JC, et al. Nondiagnostic fine-needle aspirations of the thyroid: is the risk of malignancy higher? J Surg Res 2013; 184:746–750.
Eun NL, Yoo MR, Gweon HM, et al. Thyroid nodules with nondiagnostic results on repeat fine-needle aspiration biopsy: which nodules should be considered for repeat biopsy or surgery rather than follow-up? Ultrasonography 2016; 35:234–243.
Woo SH, Kim KH, Kim RB. Thyroid nodules with repeat nondiagnostic cytologic results: the role of clinical and ultrasonographic findings. World J Surg 2015; 39:1721–1727.
McHenry CR, Slusarczyk SJ, Khiyami A. Recommendations for management of cystic thyroid disease. Surgery 1999; 126:1167–1171.
McGill JF, Sturgeon C, Angelos P. Metastatic struma ovarii treated with total thyroidectomy and radioiodine ablation. Endocr Pract 2009; 15:167–173.
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998; 228:320–330.
Stavrakis AI, Ituarte PH, Ko CY, Yeh MW. Surgeon volume as a predictor of outcomes in inpatient and outpatient endocrine surgery. Surgery 2007; 142:887–899.
Kandil E, Noureldine SI, Abbas A, Tufano RP. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery 2013; 154:1346–1352.
Adkisson CD, Howell GM, McCoy KL, et al. Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. Surgery 2014; 156:1453–1459.
Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg 2017; 265:402–407.
Nouraei SA, Virk JS, Middleton SE, et al. A national analysis of trends, outcomes and volume-outcome relationships in thyroid surgery. Clin Otolaryngol 2017; 42:354–365.
Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. The importance of surgical volume on outcomes in thyroid surgery revisited: old is in again: editorial response to “what's old is new again” by Julie Ann Sosa (doi: 10.1245/s10434–014–3850-z). Ann Surg Oncol 2014; 21:3721–3722.
Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol 2014; 21:3844–3852.
Sabaretnam M, Mishra A, Chand G. Assessment of swallowing function impairment in patients with benign goiters and impact of thyroidectomy: a case control study. World J Surg 2012; 36:1293–1299.
Reiher AE, Mazeh H, Schaefer S, et al. Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid 2012; 22:1160–1164.
Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves’ disease: a meta-analysis. J Surg Res 2000; 90:161–165.
Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K. Thyroid surgery for Graves’ disease and Graves’ ophthalmopathy. Cochrane Database Syst Rev 2015; (11):CD010576.
Uruno T, Masaki C, Suzuki A, et al. Antimicrobial prophylaxis for the prevention of surgical site infection after thyroid and parathyroid surgery: a prospective randomized trial. World J Surg 2015; 39:1282–1287.
Dionigi G, Rovera F, Boni L, Castano P, Dionigi R. Surgical site infections after thyroidectomy. Surg Infect (Larchmt) 2006; 7: (suppl 2): S117–S120.
ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm 1999; 56:1839–1888.
Gentile I, Rosato L, Avenia N, et al. Do Italian surgeons use antibiotic prophylaxis in thyroid surgery? Results from a national study (UEC—Italian Endocrine Surgery Units Association). Ann Ital Chir 2014; 85:33–37.
Moalem J, Ruan DT, Farkas RL, et al. Patterns of antibiotic prophylaxis use for thyroidectomy and parathyroidectomy: results of an international survey of endocrine surgeons. J Am Coll Surg 2010; 210:949–956.
Elfenbein DM, Schneider DF, Chen H, Sippel RS. Surgical site infection after thyroidectomy: a rare but significant complication. J Surg Res 2014; 190:170–176.
Cheng SP, Liu TP, Yang PS, Lee KS, Liu CL. Effect of perioperative dexamethasone on subjective voice quality after thyroidectomy: a meta-analysis and systematic review. Langenbecks Arch Surg 2015; 400:929–936.
Tarantino I, Warschkow R, Beutner U, et al. Efficacy of a single preoperative dexamethasone dose to prevent nausea and vomiting after thyroidectomy (the tPONV study): a randomized, double-blind, placebo-controlled clinical trial. Ann Surg 2015; 262:934–940.
Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000; 91:136–139.
Lachanas VA, Exarchos S, Tsiouvaka S, et al. Does perioperative dexamethasone affect voice-related quality of life after thyroidectomy? Eur Arch Otorhinolaryngol 2014; 271:3073–3076.
Schietroma M, Cecilia EM, Carlei F, et al. Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial. JAMA Otolaryngol Head Neck Surg 2013; 139:471–478.
Worni M, Schudel HH, Seifert E, et al. Randomized controlled trial on single dose steroid before thyroidectomy for benign disease to improve postoperative nausea, pain, and vocal function. Ann Surg 2008; 248:1060–1066.
Erbil Y, Giriş M, Salmaslioglu A, et al. The effect of anti-thyroid drug treatment duration on thyroid gland microvessel density and intraoperative blood loss in patients with Graves’ disease. Surgery 2008; 143:216–225.
Erbil Y, Ozluk Y, Giriş M, et al. Effect of lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves’ disease. J Clin Endocrinol Metab 2007; 92:2182–2189.
Ansaldo GL, Pretolesi F, Varaldo E, et al. Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. J Am Coll Surg 2000; 191:607–612.
Yilmaz Y, Kamer KE, Ureyen O, Sari E, Acar T, Karahalli O. The effect of preoperative Lugol's iodine on intraoperative bleeding in patients with hyperthyroidism. Ann Med Surg (Lond) 2016; 9:53–57.
Shinall MC Jr, Broome JT, Baker A, Solorzano CC. Is potassium iodide solution necessary before total thyroidectomy for Graves disease? Ann Surg Oncol 2013; 20:2964–2967.
Simsir IY, Ozdemir M, Duman S, Erdogan M, Donmez A, Ozgen AG. Therapeutic plasmapheresis in thyrotoxic patients. Endocrine 2018; 62:144–148.
Schafer AL, Weaver CM, Black DM, et al. Intestinal calcium absorption decreases dramatically after gastric bypass surgery despite optimization of vitamin D Status. J Bone Miner Res 2015; 30:1377–1385.
Goldenberg D, Ferris RL, Shindo ML, et al. Thyroidectomy in patients who have undergone gastric bypass surgery. Head Neck 2018; 40:1237–1244.
Campos GM, Ziemelis M, Paparodis R, Ahmed M, Davis DB. Laparoscopic reversal of Roux-en-Y gastric bypass: technique and utility for treatment of endocrine complications. Surg Obes Relat Dis 2014; 10:36–43.
Gooi Z, Ward BK, Mener DJ, Ozgursoy OB, Pai SI. A staged thyroidectomy approach for gastric bypass patients. Laryngoscope 2015; 125:1028–1030.
Roh JL, Park CI. Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg 2006; 192:675–678.
Tartaglia F, Giuliani A, Sgueglia M, Biancari F, Juvonen T, Campana FP. Randomized study on oral administration of calcitriol to prevent symptomatic hypocalcemia after total thyroidectomy. Am J Surg 2005; 190:424–429.
Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol 2015; 22:952–958.
Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP. Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br J Surg 2014; 101:307–320.
Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924–4927.
Alsaffar H, Wilson L, Kamdar DP, Sultanov F, Enepekides D, Higgins KM. Informed consent: do information pamphlets improve post-operative risk-recall in patients undergoing total thyroidectomy: prospective randomized control study. J Otolaryngol Head Neck Surg 2016; 45:14.
Falagas ME, Korbila IP, Giannopoulou KP, Kondilis BK, Peppas G. Informed consent: how much and what do patients understand? Am J Surg 2009; 198:420–435.
Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol 2008; 9:485–493.
Angelos P, DaRosa DA, Bentram D, Sherman H. Residents seeking informed consent: Are they adequately knowledgeable? Curr Surg 2002; 59:115–118.
Roy M, Rajamanickam V, Chen H, Sippel R. Is DVT prophylaxis necessary for thyroidectomy and parathyroidectomy? Surgery 2010; 148:1163–1168.
Limongelli P, Tolone S, Gubitosi A. Relationship between postoperative venous thromboembolism and hemorrhage in patients undergoing total thyroidectomy without preoperative prophylaxis. Int J Surg 2014; 12: (suppl 1): S198–S201.
Macht R, Gardner I, Talutis S, Rosenkranz P, Doherty G, McAneny D. Evaluation of a standardized risk-based venous thromboembolism prophylaxis protocol in the setting of thyroid and parathyroid surgery. J Am Coll Surg 2017; 224:1029–1035.
Pardal-Refoyo JL, Cuello-Azcarate JJ, Santiago-Pena LF. Development of a checklist in risk management in thyroidectomy. Endocrinol Nutr 2014; 61:445–454.
Carty SE, Doherty GM, Inabnet WB, 3rd, et al. American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. Thyroid 2012; 22:395–399.
Miller BS, Doherty GM. An examination of recently revised differentiated thyroid cancer guidelines. Curr Opin Oncol 2011; 23:1–6.
Zeuren R, Biagini A, Grewal RK, et al. RAI thyroid bed uptake after total thyroidectomy: a novel SPECT-CT anatomic classification system. Laryngoscope 2015; 125:2417–2424.
Molina G, Jiang W, Edmondson L, et al. Implementation of the surgical safety Checklist in South Carolina Hospitals is associated with improvement in perceived perioperative safety. J Am Coll Surg 2016; 222:725–736.
Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009; 360:491–499.
Lang BH, Ng SH, Wong KP. Pain and surgical outcomes with and without neck extension in standard open thyroidectomy: a prospective randomized trial. Head Neck 2015; 37:407–412.
Chiang FY, Lu IC, Kuo WR, Lee KW, Chang NC, Wu CW. The mechanism of recurrent laryngeal nerve injury during thyroid surgery—the application of intraoperative neuromonitoring. Surgery 2008; 143:743–749.
Dralle H, Sekulla C, Haerting J, et al. Risk factors of paralysis and functional outcome after recurrent laryngeal nerve monitoring in thyroid surgery. Surgery 2004; 136:1310–1322.
Portinari M, Carcoforo P. The application of drains in thyroid surgery. Gland Surg 2017; 6:563–573.
Tandon S, Shahab R, Benton JI, Ghosh SK, Sheard J, Jones TM. Fine-needle aspiration cytology in a regional head and neck cancer center: comparison with a systematic review and meta-analysis. Head Neck 2008; 30:1246–1252.
Ha EJ, Baek JH, Lee JH, et al. Complications following US-guided core-needle biopsy for thyroid lesions: a retrospective study of 6,169 consecutive patients with 6,687 thyroid nodules. Eur Radiol 2017; 27:1186–1194.
Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid 2012; 22:468–475.
Novoa E, Gürtler N, Arnoux A, Kraft M. Role of ultrasound-guided core-needle biopsy in the assessment of head and neck lesions: a meta-analysis and systematic review of the literature. Head Neck 2012; 34:1497–1503.
Wolinski K, Stangierski A, Ruchala M. Comparison of diagnostic yield of core-needle and fine-needle aspiration biopsies of thyroid lesions: systematic review and meta-analysis. Eur Radiol 2017; 27:431–436.
Sharma A, et al. Presenting features of thyroid lymphoma: the mayo clinic experience. Thyroid 2015; 25:A197.
Ha EJ, Baek JH, Lee JH, et al. Core needle biopsy could reduce diagnostic surgery in patients with anaplastic thyroid cancer or thyroid lymphoma. Eur Radiol 2016; 26:1031–1036.
Swerdlow SH, CE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4 ed. Vol. 2. 2008, Lyon, France: IARC Press. 439.
Peng Y, Wang HH. A meta-analysis of comparing fine-needle aspiration and frozen section for evaluating thyroid nodules. Diagnostic Cytopathol 2008; 36:916–920.
Udelsman R, Westra WH, Donovan PI, et al. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg 2001; 233:716–722.
LiVolsi VA, Baloch ZW. Use and abuse of frozen section in the diagnosis of follicular thyroid lesions. Endocr Pathol 2005; 16:285–293.
Park YM, Wang SG, Goh JY, Shin DH, Kim IJ, Lee BJ. Intraoperative frozen section for the evaluation of extrathyroidal extension in papillary thyroid cancer. World J Surg 2015; 39:187–193.
Balasubramanian SP, Harrison BJ. Systematic review and meta-analysis of sentinel node biopsy in thyroid cancer. Br J Surg 2011; 98:334–344.
Westra WH, Pritchett DD, Udelsman R. Intraoperative confirmation of parathyroid tissue during parathyroid exploration: a retrospective evaluation of the frozen section. Am J Surg Pathol 1998; 22:538–544.
Bian XH, Li SJ, Zhou L, et al. Applicability of rapid intraoperative parathyroid hormone assay through fine needle aspiration to identify parathyroid tissue in thyroid surgery. Exp Ther Med 2016; 12:4072–4076.
Su HK, Wenig BM, Haser GC, et al. Inter-observer variation in the pathologic identification of minimal extrathyroidal extension in papillary thyroid carcinoma. Thyroid 2016; 26:512–517.
Du E, Wenig BM, Su HK, et al. Inter-observer variation in the pathologic identification of extranodal extension in nodal metastasis from papillary thyroid carcinoma. Thyroid 2016; 26:816–819.
Hamady ZZ, Mather N, Lansdown MR, Davidson L, Maclennan KA. Surgical pathological second opinion in thyroid malignancy: impact on patients’ management and prognosis. Eur J Surg Oncol 2005; 31:74–77.
Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol 2002; 117:143–150.
DeLellis, RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. 2004, IARC Press: Lyon, France.
Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006; 107:1255–1264.
Lang W, Georgii A, Stauch G, Kienzle E. The differentiation of atypical adenomas and encapsulated follicular carcinomas in the thyroid gland. Virchows Arch A Pathol Anat Histol 1980; 385:125–141.
Yamashina M. Follicular neoplasms of the thyroid. Total circumferential evaluation of the fibrous capsule. Am J Surg Pathol 1992; 16:392–400.
Kim HJ, Sung JY, Oh YL, et al. Association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. Head Neck 2014; 36:1695–1700.
O’Neill CJ, Vaughan L, Learoyd DL, et al. Management of follicular thyroid carcinoma should be individualised based on degree of capsular and vascular invasion. Eur J Surg Oncol 2011; 37:181–185.
D’Avanzo A, Treseler P, Ituarte PH, et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004; 100:1123–1129.
Podda M, Saba A, Porru F, Reccia I, Pisanu A. Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors. World J Surg Oncol 2015; 13:193.
Ito Y, Hirokawa M, Masuoka H, et al. Prognostic factors of minimally invasive follicular thyroid carcinoma: extensive vascular invasion significantly affects patient prognosis. Endocr J 2013; 60:637–642.
Maximo V, Máximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simões M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol 2002; 160:1857–1865.
Lloyd RV, Osamura RY, Klöppel G, Rosai J. World Health Organization Classification of Tumours of Endocrine Organs. 4th ed.Lyon: IARC; 2017.
Ríos A, Rodríguez JM, Ferri B, Matínez-Barba E, Febrero B, Parrilla P. Are prognostic scoring systems of value in patients with follicular thyroid carcinoma? Eur J Endocrinol 2013; 169:821–827.
D’Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004; 14:453–458.
Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hurthle cell cancer. World J Surg 2004; 28:1266–1270.
Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988; 67:501–508.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see commetns]. Cancer 1998; 83:2638–2648.
Amin MB and Edge SB. AJCC cancer staging manual. Eighth ed. New York: Springer; 2017.
Seethala RR, Asa SL, Carty SE, et al. Protocol for the Examination of Specimens From Patients With Carcinomas of the Thyroid Gland. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution Folders/WebContent/pdf/cp-thyroid-16protocol-3200.pdf. Accessed July 19, 2019.
Kahn C, Simonella L, Sywak M, Boyages S, Ung O, O’Connell D. Postsurgical pathology reporting of thyroid cancer in New South Wales, Australia. Thyroid 2012; 22:604–610.
Cancer Protocol Templates. Cancer Protocol Templates 2017. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution Folders/WebContent/pdf/cp-thyroid-17protocol-4000.pdf. Accessed July 19, 2019.
Mainthia R, Wachtel H, Chen Y, et al. Evaluating the projected surgical impact of reclassifying noninvasive encapsulated follicular variant of papillary thyroid cancer as noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Surgery 2018; 163:60–65.
Alves VAF, Kakudo K, LiVolsi V, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): achieving better agreement by refining diagnostic criteria. Clinics (Sao Paulo) 2018; 73:e576.
Johnson DN, Furtado LV, Long BC, et al. Noninvasive follicular thyroid neoplasms with papillary-like nuclear features are genetically and biologically similar to adenomatous nodules and distinct from papillary thyroid carcinomas with extensive follicular growth. Arch Pathol Lab Med 2018; 142:838–850.
Chen J, Tward JD, Shrieve DC, Hitchcock YJ. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983–2002. Am J Clin Oncol 2008; 31:460–464.
McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001; 130:1028–1034.
Yoshida A, Kamma H, Asaga T, et al. Proliferative activity in thyroid tumors. Cancer 1992; 69:2548–2552.
Mete O, Asa SL. Precursor lesions of endocrine system neoplasms. Pathology 2013; 45:316–330.
Perry A, Molberg K, Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 1996; 77:750–756.
Phitayakorn R, Faquin W, Wei N, Barbesino G, Stephen AE. Thyroid-associated paragangliomas. Thyroid 2011; 21:725–733.
Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999; 229:880–887.
Robinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How many lymph nodes are enough? assessing the adequacy of lymph node yield for papillary thyroid cancer. J Clin Oncol 2016; 34:3434–3439.
Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017; 161:137–146.
Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004; 136:1183–1191.
Lee DW, Ji YB, Sung ES, et al. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. Eur J Surg Oncol 2013; 39:191–196.
Stack BC Jr, Ferris RL, Goldenberg D, et al. American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid 2012; 22:501–508.
Fraser S, Zaidi N, Norlén O, et al. Incidence and risk factors for occult level 3 lymph node metastases in papillary thyroid cancer. Ann Surg Oncol 2016; 23:3587–3592.
Moo TA, Umunna B, Kato M, et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg 2009; 250:403–408.
Chae BJ, Jung CK, Lim DJ, et al. Performing contralateral central lymph node dissection in papillary thyroid carcinoma: a decision approach. Thyroid 2011; 21:873–877.
Song CM, Lee DW, Ji YB, et al. Frequency and pattern of central lymph node metastasis in papillary carcinoma of the thyroid isthmus. Head Neck 2016; 38: (suppl 1): E412–E416.
Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003; 88:2070–2075.
Lang BH, Lee GC, Ng CP, et al. Evaluating the morbidity and efficacy of reoperative surgery in the central compartment for persistent/recurrent papillary thyroid carcinoma. World J Surg 2013; 37:2853–2859.
Khokhar MT, Day KM, Sangal RB, et al. Preoperative high-resolution ultrasound for the assessment of malignant central compartment lymph nodes in papillary thyroid cancer. Thyroid 2015; 25:1351–1354.
Moreno MA, Edeiken-Monroe BS, Siegel ER, et al. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. Thyroid 2012; 22:347–355.
Shen WT, Ogawa L, Ruan D, Suh I, Duh QY, Clark OH. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery 2010; 148:398–403.
Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009; 19:683–689.
Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann Surg Oncol 2012; 19:4217–4222.
Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol 2013; 20:3477–3483.
Zhao WJ, Luo H, Zhou YM, Dai WY, Zhu JQ. Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: an updated meta-analysis. Eur J Surg Oncol 2017; 43:1989–2000.
Hall CM, Snyder SK, Maldonado YM, Lairmore TC. Routine central lymph node dissection with total thyroidectomy for papillary thyroid cancer potentially minimizes level VI recurrence. Surgery 2016; 160:1049–1058.
Hughes DT, Rosen JE, Evans DB, Grubbs E, Wang TS, Solórzano CC. Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence. Ann Surg Oncol 2018; 25:2526–2534.
Viola D, Materazzi G, Valerio L, et al. Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. J Clin Endocrinol Metab 2015; 100:1316–1324.
Nixon IJ, Wang LY, Ganly I, et al. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. Br J Surg 2016; 103:218–225.
Kim SK, Woo JW, Lee JH, et al. Prophylactic central neck dissection might not be necessary in papillary thyroid carcinoma: analysis of 11,569 cases from a single institution. J Am Coll Surg 2016; 222:853–864.
Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): what changed and why? Thyroid 2017; 27:751–756.
Tisell LE, Nilsson B, Mölne J, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996; 20:854–859.
Dobrinja C, Troian M, Cipolat Mis T, et al. Rationality in prophylactic central neck dissection in clinically node-negative (cN0) papillary thyroid carcinoma: is there anything more to say? A decade experience in a single-center. Int J Surg 2017; 41: (suppl 1): S40–S47.
Said M, Fujimoto M, Franken C, Woo S, Vuong B, Haigh PI. Preferential use of total thyroidectomy without prophylactic central lymph node dissection for early-stage papillary thyroid cancer: oncologic outcomes in an integrated health plan. Perm J 2016; 20:22–26.
Suman P, Wang CH, Abadin SS, Moo-Young TA, Prinz RA, Winchester DJ. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: a National Cancer Data Base (NCDB) study. Surgery 2016; 159:31–39.
Sun W, Lan X, Zhang H, et al. Risk factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. PLoS One 2015; 10:e0139021.
Cabrera RN, Chone CT, Zantut-Wittmann D, et al. Value of sentinel lymph node biopsy in papillary thyroid cancer: initial results of a prospective trial. Eur Arch Otorhinolaryngol 2015; 272:971–979.
Iyer NG, Shaha AR, Ferlito A, et al. Delphian node metastasis in head and neck cancers—oracle or myth? J Surg Oncol 2010; 102:354–358.
Kim WW, Yang SI, Kim JH, Choi YS, Park YH, Kwon SK. Experience and analysis of Delphian lymph node metastasis in patients with papillary thyroid carcinoma. World J Surg Oncol 2012; 10:226.
Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144–1152.
Javid M, Graham E, Malinowski J, et al. Dissection of levels II through V is required for optimal outcomes in patients with lateral neck lymph node metastasis from papillary thyroid carcinoma. J Am Coll Surg 2016; 222:1066–1073.
McNamara WF, Wang LY, Palmer FL, et al. Pattern of neck recurrence after lateral neck dissection for cervical metastases in papillary thyroid cancer. Surgery 2016; 159:1565–1571.
Welch K, McHenry CR. Selective lateral compartment neck dissection for thyroid cancer. J Surg Res 2013; 184:193–199.
Eskander A, Merdad M, Freeman JL, Witterick IJ. Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis. Thyroid 2013; 23:583–592.
Caron NR, Tan YY, Ogilvie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary? World J Surg 2006; 30:833–840.
Merdad M, Eskander A, Kroeker T, Freeman JL. Metastatic papillary thyroid cancer with lateral neck disease: pattern of spread by level. Head Neck 2013; 35:1439–1442.
Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol 2008; 158:551–560.
Sugitani I, Fujimoto Y, Yamada K, Yamamoto N. Prospective outcomes of selective lymph node dissection for papillary thyroid carcinoma based on preoperative ultrasonography. World J Surg 2008; 32:2494–2502.
Ito Y, Miyauchi A, Kudo T, Kihara M, Fukushima M, Miya A. The effectiveness of prophylactic modified neck dissection for reducing the development of lymph node recurrence of papillary thyroid Carcinoma. World J Surg 2017; 41:2283–2289.
Tuttle RM, Ball DW, Byrd D, et al. Medullary carcinoma. J Natl Compr Canc Netw 2010; 8:512–530.
Glenn JA, Yen TW, Fareau GG, Carr AA, Evans DB, Wang TS. Institutional experience with lateral neck dissections for thyroid cancer. Surgery 2015; 158:972–978.
Polistena A, Monacelli M, Lucchini R, et al. Surgical morbidity of cervical lymphadenectomy for thyroid cancer: a retrospective cohort study over 25 years. Int J Surg 2015; 21:128–134.
McMullen C, Rocke D, Freeman J. Complications of bilateral neck dissection in thyroid cancer from a single high-volume center. JAMA Otolaryngol Head Neck Surg 2017; 143:376–381.
Delaney SW, Shi H, Shokrani A, Sinha UK. Management of chyle leak after head and neck surgery: review of current treatment strategies. Int J Otolaryngol 2017; 2017:8362874.
Mekel M, Stephen AE, Gaz RD, et al. Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer. Am J Surg 2010; 199:485–490.
Abboud B, Tannoury J, Sleilaty G, Daher R, Abadjian G, Ghorra C. Cervical neck dissection without drainage in papillary thyroid carcinoma. J Laryngol Otol 2013; 127:299–302.
Jain A, Singh SN, Singhal P, Sharma MP, Grover M. A prospective study on the role of octreotide in management of chyle fistula neck. Laryngoscope 2015; 125:1624–1627.
Merki V, Pichler J, Giger R, Mantokoudis G. Chylothorax in thyroid surgery: a very rare case and systematic review of the literature. J Otolaryngol Head Neck Surg 2016; 45:52.
Wang LY, Palmer FL, Nixon IJ, et al. Lateral neck lymph node characteristics prognostic of outcome in patients with clinically evident N1b papillary thyroid cancer. Ann Surg Oncol 2015; 22:3530–3536.
Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid 2013; 23:1099–1105.
Suh S, Pak K, Seok JW, Kim IJ. Prognostic value of extranodal extension in thyroid cancer: a meta-analysis. Yonsei Med J 2016; 57:1324–1328.
Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004; 135:139–148.
Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008; 144:1070–1077.
Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol 2015; 33:2370–2375.
Esfandiari NH, Hughes DT, Yin H, Banerjee M, Haymart MR. The effect of extent of surgery and number of lymph node metastases on overall survival in patients with medullary thyroid cancer. J Clin Endocrinol Metab 2014; 99:448–454.
Hughes DT, Laird AM, Miller BS, Gauger PG, Doherty GM. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Ann Surg Oncol 2012; 19:2951–2957.
Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab 2010; 95:2187–2194.
Robenshtok E, Fish S, Bach A, Domínguez JM, Shaha A, Tuttle RM. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 2012; 97:2706–2713.
Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Charboneau JW. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 2013; 154:1448–1454.
Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96:2750–2755.
Tufano RP, Clayman G, Heller KS, et al. Management of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and benefits of surgical intervention versus active surveillance. Thyroid 2015; 25:15–27.
Wagner B, Begic-Karup S, Raber W, Schneider B, Waldhäusl W, Vierhapper H. Prevalence of primary hyperparathyroidism in 13387 patients with thyroid diseases, newly diagnosed by screening of serum calcium. Exp Clin Endocrinol Diabetes 1999; 107:457–461.
Del Rio P, Arcuri MF, Bezer L, Cataldo S, Robuschi G, Sianesi M. Association between primary hyperparathyroidism and thyroid disease. Role of preoperative PTH. Ann Ital Chir 2009; 80:435–438.
Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery 2006; 140:874–881.
Zanocco K, Heller M, Sturgeon C. Cost-effectiveness of parathyroidectomy for primary hyperparathyroidism. Endocr Pract 2011; 17: (suppl 1): 69–74.
Zanocco K, Sturgeon C. How should age at diagnosis impact treatment strategy in asymptomatic primary hyperparathyroidism? A cost-effectiveness analysis. Surgery 2008; 144:290–298.
Elliott DD, Monroe DP, Perrier ND. Parathyroid histopathology: is it of any value today? J Am Coll Surg 2006; 203:758–765.
Agrawal K, Esmail AA, Gnanasegaran G, Navalkissoor S, Mittal BR, Fogelman I. Pitfalls and limitations of radionuclide imaging in endocrinology. Semin Nucl Med 2015; 45:440–457.
Barbaros U, Erbil Y, Salmashoğlu A, et al. The characteristics of concomitant thyroid nodules cause false-positive ultrasonography results in primary hyperparathyroidism. Am J Otolaryngol 2009; 30:239–243.
Chang MC, Tsai SC, Lin WY. Dual-phase 99mTc-MIBI parathyroid imaging reveals synchronous parathyroid adenoma and papillary thyroid carcinoma: a case report. Kaohsiung J Med Sci 2008; 24:542–547.
Monroe DP, Edeiken-Monroe BS, Lee JE, Evans DB, Perrier ND. Impact of preoperative thyroid ultrasonography on the surgical management of primary hyperparathyroidism. Br J Surg 2008; 95:957–960.
Sippel RS, Ozgül O, Hartig GK, Mack EA, Chen H. Risks and consequences of incidental parathyroidectomy during thyroid resection. ANZ J Surg 2007; 77:33–36.
Hone RW, Tikka T, Kaleva AI, et al. Analysis of the incidence and factors predictive of inadvertent parathyroidectomy during thyroid surgery. J Laryngol Otol 2016; 130:669–673.
Lin YS, Hsueh C, Wu HY, Yu MC, Chao TC. Incidental parathyroidectomy during thyroidectomy increases the risk of postoperative hypocalcemia. Laryngoscope 2017; 127:2194–2200.
Strichartz SD, Giuliano AE. The operative management of coexisting thyroid and parathyroid disease. Arch Surg 1990; 125:1327–1331.
Hellstrom J. Primary hyperparathyroidism; observations in a series of 50 cases. Acta Endocrinol (Copenh) 1954; 16:30–58.
Kissin M, Bakst H. Co-existing myxedema and hyperparathyroidism; case report. J Clin Endocrinol Metab 1947; 7:152–158.
Ogburn PL, Black BM. Primary hyperparathyroidism and papillary adenocarcinoma of the thyroid; report of four cases. Proc Staff Meet Mayo Clin 1956; 31:295–298.
Sitges-Serra A, Gallego-Otaegui L, Suárez S, Lorente-Poch L, Munné A, Sancho JJ. Inadvertent parathyroidectomy during total thyroidectomy and central neck dissection for papillary thyroid carcinoma. Surgery 2017; 161:712–719.
Applewhite MK, White MG, Xiong M, et al. Incidence, risk factors, and clinical outcomes of incidental parathyroidectomy during thyroid surgery. Ann Surg Oncol 2016; 23:4310–4315.
Zhou HY, He JC, McHenry CR. Inadvertent parathyroidectomy: incidence, risk factors, and outcomes. J Surg Res 2016; 205:70–75.
Goodman A, Politz D, Lopez J, Norman J. Intrathyroid parathyroid adenoma: incidence and location—the case against thyroid lobectomy. Otolaryngol Head Neck Surg 2011; 144:867–871.
Herden U, Seiler CA, Candinas D, Schmid SW. Intrathyroid adenomas in primary hyperparathyroidism: are they frequent enough to guide surgical strategy? Surg Innov 2011; 18:373–378.
Miani C, Bracale AM, Bresadola V, Motz E. Concomitant primary hyperparathyroidism, Graves’ disease and vitamin D deficiency. Acta Otorhinolaryngol Ital 2003; 23:199–202.
Riss P, Kammer M, Selberherr A, Scheuba C, Niederle B. Morbidity associated with concomitant thyroid surgery in patients with primary hyperparathyroidism. Ann Surg Oncol 2015; 22:2707–2713.
Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014; 99:3561–3569.
Kiernan CM, Schlegel C, Kavalukas S, Isom C, Peters MF, Solórzano CC. Does concomitant thyroidectomy increase risks of parathyroidectomy? J Surg Res 2016; 203:34–39.
Abboud B, Sleilaty G, Braidy C, et al. Enlarged parathyroid glands discovered in normocalcemic patients during thyroid surgery. Am J Surg 2008; 195:30–33.
Abboud B, Sleilaty G, Mansour E, et al. Prevalence and risk factors for primary hyperparathyroidism in hyperthyroid patients. Head Neck 2006; 28:420–426.
Arem R, Lim-Abrahan MA, Mallette LE, et al. Graves’ disease and primary hyperparathyroidism. Influence of hyperthyroidism on serum calcium and parathyroid hormone. Am J Med 1986; 80:693–698.
Hundley JC, Woodrum DT, Saunders BD, Doherty GM, Gauger PG. Revisiting lithium-associated hyperparathyroidism in the era of intraoperative parathyroid hormone monitoring. Surgery 2005; 138:1027–1031.
Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 2009; 33:2314–2323.
Meehan AD, Humble MB, Yazarloo P, Järhult J, Wallin G. The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units. J Clin Psychopharmacol 2015; 35:279–285.
Ibrahim Y, Mohamed SE, Deniwar A, Al-Qurayshi ZH, Kandil E. Lithium-associated hyperparathyroidism: a pooled analysis. ORL J Otorhinolaryngol Relat Spec 2015; 77:273–280.
Marti JL, Yang CS, Carling T, et al. Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol 2012; 19:3465–3471.
Wade TJ, Yen TW, Amin AL, et al. Focused parathyroidectomy with intraoperative parathyroid hormone monitoring in patients with lithium-associated primary hyperparathyroidism. Surgery 2013; 153:718–722.
Akerstrom G, Stalberg P. Surgical management of MEN-1 and -2: state of the art. Surg Clin North Am 2009; 89:1047–1068.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001; 86:5658–5671.
American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565–612.
Vaidya B, Pearce SH. Diagnosis and management of thyrotoxicosis. BMJ 2014; 349:g5128.
Samarasinghe S, Meah F, Singh V, et al. Biotin interference with routine clinical immunoassays: understand the causes and mitigate the risks. Endocr Pract 2017; 23:989–998.
Snyder S, Govednik C, Lairmore T, et al. Total thyroidectomy as primary definitive treatment for Graves’ hyperthyroidism. Am Surg 2013; 79:1283–1288.
Genovese BM, Noureldine SI, Gleeson EM, et al. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol 2013; 20:660–667.
Rivkees SA. 63 years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. Int J Pediatr Endocrinol 2010; 2010:658267.
Huang SM, Liao WT, Lin CF, et al. Effectiveness and mechanism of preoperative lugol solution for reducing thyroid blood flow in patients with euthyroid Graves’ Disease. World J Surg 2016; 40:505–509.
Whalen G, Sullivan M, Maranda L, Quinlan R, Larkin A. Randomized trial of a short course of preoperative potassium iodide in patients undergoing thyroidectomy for Graves’ disease. Am J Surg 2017; 213:805–809.
Zanocco K, Heller M, Elaraj D, Sturgeon C. Is subtotal thyroidectomy a cost-effective treatment for Graves disease? A cost-effectiveness analysis of the medical and surgical treatment options. Surgery 2012; 152:164–172.
Donovan PJ, McLeod DS, Little R, Gordon L. Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves’ disease. Eur J Endocrinol 2016; 175:595–603.
Burch HB, Cooper DS. Management of Graves disease: a review. JAMA 2015; 314:2544–2554.
Hookham J, Truran P, Allahabadia A, Balasubramanian SP. Patients’ perceptions and views of surgery and radioiodine ablation in the definitive management of Graves’ disease. Postgrad Med J 2017; 93:266–270.
Maia AL, Scheffel RS, Meyer EL, et al. The Brazilian consensus for the diagnosis and treatment of hyperthyroidism: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Arq Bras Endocrinol Metabol 2013; 57:205–232.
Negro R, Attanasio R, Grimaldi F, et al. A 2015 Italian survey of clinical practice patterns in the management of Graves’ disease: comparison with European and North American Surveys. Eur Thyroid J 2016; 5:112–119.
Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 2013; 98:3671–3677.
Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves’ hyperthyroidism: a historical cohort study. Thyroid 2017; 27:497–505.
Happel C, Korkusuz H, Kranert WT, Grünwald F. Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy for treatment of hyper- and hypofunctioning thyroid nodules. Nuklearmedizin 2014; 53:N48–N49.
Bojic T, Paunovic I, Diklic A, et al. Total thyroidectomy as a method of choice in the treatment of Graves’ disease—analysis of 1432 patients. BMC Surg 2015; 15:39.
Liu J, Sun W, Dong W, et al. Risk factors for post-thyroidectomy haemorrhage: a meta-analysis. Eur J Endocrinol 2017; 176:591–602.
Phitayakorn R, Morales-Garcia D, Wanderer J, et al. Surgery for Graves’ disease: a 25-year perspective. Am J Surg 2013; 206:669–673.
Quérat C, Germain N, Dumollard JM, Estour B, Peoc’h M, Prades JM. Surgical management of hyperthyroidism. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132:63–66.
Yamanouchi K, Minami S, Hayashida N, Sakimura C, Kuroki T, Eguchi S. Predictive factors for intraoperative excessive bleeding in Graves’ disease. Asian J Surg 2015; 38:1–5.
Yamanouchi K, Minami S, Kuba S, et al. Evaluation of the operative methods for Graves’ disease. Minerva Chir 2015; 70:77–81.
Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol 2012; 126:701–705.
Huang CJ, Tseng CL, Chu CH, Huang DF, Huang CC, Lin LY. Adherence to guidelines in monitoring amiodarone-induced thyroid dysfunction. J Eval Clin Pract 2017; 23:108–113.
McManus C, Luo J, Sippel R, Chen H. Is thyroidectomy in patients with Hashimoto thyroiditis more risky? J Surg Res 2012; 178:529–532.
Shih ML, Lee JA, Hsieh CB, et al. Thyroidectomy for Hashimoto's thyroiditis: complications and associated cancers. Thyroid 2008; 18:729–734.
Liu J, Bargren A, Schaefer S, Chen H, Sippel RS. Total thyroidectomy: a safe and effective treatment for Graves’ disease. J Surg Res 2011; 168:1–4.
Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 2013; 79:739–746.
Tezelman S, Borucu I, Senyurek Giles Y, Tunca F, Terzioglu T. The change in surgical practice from subtotal to near-total or total thyroidectomy in the treatment of patients with benign multinodular goiter. World J Surg 2009; 33:400–405.
Kus LH, Hopman WM, Witterick IJ, Freeman JL. Quality-of-life outcomes in Graves disease patients after total thyroidectomy. Ear Nose Throat J 2017; 96:E8–E15.
Piga M, Serra A, Boi F, Tanda ML, Martino E, Mariotti S. Amiodarone-induced thyrotoxicosis. A review. Minerva Endocrinol 2008; 33:213–228.
Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 2004; 28:1083–1087.
Kaderli RM, Fahrner R, Christ ER, et al. Total thyroidectomy for amiodarone-induced thyrotoxicosis in the hyperthyroid state. Exp Clin Endocrinol Diabetes 2016; 124:45–48.
Lorberboym M, Schachter P. Drug-induced thyrotoxicosis: the surgical option. Isr Med Assoc J 2007; 9:79–82.
Franzese CB, Fan CY, Stack BC Jr. Surgical management of amiodarone-induced thyrotoxicosis. Otolaryngol Head Neck Surg 2003; 129:565–570.
Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 2002; 12:523–525.
Perumal B, Meyer DR. Treatment of severe thyroid eye disease: a survey of the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS). Ophthal Plast Reconstr Surg 2015; 31:127–131.
Smith TJ, Hegedus L. Graves’ disease. N Engl J Med 2016; 375:1552–1565.
Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 2008; 18:333–346.
Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73:639–644.
Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 1997; 47:9–14.
Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves’ ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005; 63:323–328.
Stein JD, Childers D, Gupta S, et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol 2015; 133:290–296.
Abe Y, Sato H, Noguchi M, et al. Effect of subtotal thyroidectomy on natural history of ophthalmopathy in Graves’ disease. World J Surg 1998; 22:714–717.
Youngwirth LM, Adam MA, Scheri RP, Roman SA, Sosa JA. Patients treated at low-volume centers have higher rates of incomplete resection and compromised outcomes: analysis of 31,129 patients with papillary thyroid cancer. Ann Surg Oncol 2016; 23:403–409.
Campbell MJ, McCoy KL, Shen WT, et al. A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery 2013; 154:1283–1289.
Quimby AE, McCoy KL, Shen Wells ST, Hearn M, Javidnia H, Johnson-Obaseki S. Is there a group of patients at greater risk for hematoma following thyroidectomy? A systematic review and meta-analysis. Laryngoscope 2017; 127:1483–1490.
Marcinkowska M, Sniecikowska B, Zygmunt A, Brzezinski J, Dedecjus M, Lewinski A. Postoperative hypoparathyroidism in patients after total thyroidectomy—retrospective analysis. Neuro Endocrinol Lett 2017; 38:488–494.
Miah MS, Mahendran S, Mak C, Leese G, Smith D. Pre-operative serum alkaline phosphatase as a predictive indicator of post-operative hypocalcaemia in patients undergoing total thyroidectomy. J Laryngol Otol 2015; 129:1128–1132.
Burnett HF, Mabry CD, Westbrook KC. Hypocalcemia after thyroidectomy: mechanisms and management. South Med J 1977; 70:1045–1048.
See AC, Soo KC. Hypocalcaemia following thyroidectomy for thyrotoxicosis. Br J Surg 1997; 84:95–97.
Velentzas C, Oreopoulos DG. Thyrotoxic osteodystrophy: a perplexing type of metabolic bone disease. Clin Invest Med 1978; 1:53–55.
Wilkin TJ, Isles TE, Paterson CR, Crooks J, Beck J. Post-thyroidectomy hypocalcaemia: a feature of the operation or the thyroid disorder? Lancet 1977; 1:621–623.
Bisbocci D, Gallo V, Damiano P, et al. Spontaneous release of interleukin 1 beta from human blood monocytes in thyrotoxic osteodystrophy. J Endocrinol Invest 1996; 19:511–515.
Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. Thyroid 2004; 14:933–945.
Schabram J, Vorlander C, Wahl RA. Differentiated operative strategy in minimally invasive, video-assisted thyroid surgery results in 196 patients. World J Surg 2004; 28:1282–1286.
van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves’ disease. J Endocrinol Invest 1992; 15:797–800.
Chiang FY, Lin JC, Wu CW, et al. Morbidity after total thyroidectomy for benign thyroid disease: comparison of Graves’ disease and non-Graves’ disease. Kaohsiung J Med Sci 2006; 22:554–559.
Enomoto K, Uchino S, Watanabe S, Enomoto Y, Noguchi S. Recurrent laryngeal nerve palsy during surgery for benign thyroid diseases: risk factors and outcome analysis. Surgery 2014; 155:522–528.
Joliat GR, Guarnero V, Demartines N, Schweizer V, Matter M. Recurrent laryngeal nerve injury after thyroid and parathyroid surgery: Incidence and postoperative evolution assessment. Medicine (Baltimore) 2017; 96:e6674.
Welch KC, McHenry CR. Total thyroidectomy: is morbidity higher for Graves’ disease than nontoxic goiter? J Surg Res 2011; 170:96–99.
Akamizu T. Thyroid storm: A Japanese perspective. Thyroid 2018; 28:32–40.
Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. J Clin Endocrinol Metab 2015; 100:451–459.
Bacuzzi A, Dionigi G, Guzzetti L, De Martino AI, Severgnini P, Cuffari S. Predictive features associated with thyrotoxic storm and management. Gland Surg 2017; 6:546–551.
Chiha M, Samarasinghe S, Kabaker AS. Thyroid storm: an updated review. J Intensive Care Med 2015; 30:131–140.
Ono Y, Ono S, Yasunaga H, Matsui H, Fushimi K, Tanaka Y. Factors associated with mortality of thyroid storm: analysis using a National Inpatient Database in Japan. Medicine (Baltimore) 2016; 95:e2848.
Satoh T, Isozaki O, Suzuki A, et al. 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). Endocr J 2016; 63:1025–1064.
Strowd SM, Majewski MB, Asteris J. Malignant hyperthermia versus thyroid storm in a patient with symptomatic Graves Disease: a case report. A A Case Rep 2018; 10: 97–99.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015; 10:93.
Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1:238–249.
Andersen SL, Lönn S, Vestergaard P, Törring O. Birth defects after use of antithyroid drugs in early pregnancy: a Swedish nationwide study. Eur J Endocrinol 2017; 177:369–378.
Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013; 98:4373–4381.
Laurberg P, Andersen SL. Graves’-Basedow disease in pregnancy. New trends in the management and guidance to reduce the risk of birth defects caused by antithyroid drugs. Nuklearmedizin 2015; 54:106–111.
Laurberg P, Andersen SL. Antithyroid drug use in pregnancy and birth defects: why some studies find clear associations, and some studies report none. Thyroid 2015; 25:1185–1190.
Milham S Jr. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy. Teratology 1985; 32:321.
Wolf D, Foulds N, Daya H. Antenatal carbimazole and choanal atresia: a new embryopathy. Arch Otolaryngol Head Neck Surg 2006; 132:1009–1011.
Yoshihara A, Noh J, Yamaguchi T, et al. Treatment of graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 2012; 97:2396–2403.
Yoshihara A, Noh JY, Watanabe N, et al. Substituting potassium iodide for methimazole as the treatment for Graves’ disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. Thyroid 2015; 25:1155–1161.
Jenkins TM, Mackey SF, Benzoni EM, Tolosa JE, Sciscione AC. Non-obstetric surgery during gestation: risk factors for lower birthweight. Aust N Z J Obstet Gynaecol 2003; 43:27–31.
Kuy S, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg 2009; 144:399–406.
ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. Obstet Gynecol 2011; 117(2 pt 1): 420–1.
Alamdari S, Azizi F, Delshad H, Sarvghadi F, Amouzegar A, Mehran L. Management of hyperthyroidism in pregnancy: comparison of recommendations of american thyroid association and endocrine society. J Thyroid Res 2013; 2013:878467.
Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27:315–389.
De Groot L, Abalovich M, Alexander EK, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:2543–2565.
Hamilton NT, Paterson PJ, Breidahl HD. Thyroidectomy during pregnancy. Med J Aust 1968; 1:431–433.
Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg 2005; 190:467–473.
Weingold AB. Appendicitis in pregnancy. Clin Obstet Gynecol 1983; 26:801–809.
Polak M, Luton D. Fetal thyroidology. Best Pract Res Clin Endocrinol Metab 2014; 28:161–173.
Ferianec V, Papcun P, Grochal F, Schenková K, Bártová M. Prenatal diagnosis and successful intrauterine treatment of severe congenital hypothyroidism associated with fetal goiter. J Obstet Gynaecol Res 2017; 43:232–237.
Fujii S, Nagaishi J, Mukuda N, et al. Evaluation of fetal thyroid with 3D gradient echo T1-weighted MR imaging. Magn Reson Med Sci 2017; 16:203–208.
Gietka-Czernel M, Dębska M, Kretowicz P, Jastrzębska H, Zgliczyński W. Increased size and vascularisation, plus decreased echogenicity, of foetal thyroid in two-dimensional ultrasonography caused by maternal Graves’ disease. Endokrynol Pol 2014; 65:64–68.
Gietka-Czernel M, Dębska M, Kretowicz P, Zgliczyński W, Ołtarzewski M. Hyperthyroidism during pregnancy—the role of measuring maternal TSH receptor antibodies and foetal ultrasound monitoring. Endokrynol Pol 2014; 65:259–268.
Zielinski R, Respondek-Liberska M. The role of prenatal ultrasound assessment in management of fetal cervicofacial tumors. Arch Med Sci 2016; 12:850–855.
Reitman E, Flood P. Anaesthetic considerations for non-obstetric surgery during pregnancy. Br J Anaesth 2011; 107: (suppl 1): i72–i78.
Van De Velde M, De Buck F. Anesthesia for non-obstetric surgery in the pregnant patient. Minerva Anestesiol 2007; 73:235–240.
Sorensen JR, Sørensen JR, Hegedüs L, Kruse-Andersen S, Godballe C, Bonnema SJ. The impact of goitre and its treatment on the trachea, airflow, oesophagus and swallowing function. A systematic review. Best Pract Res Clin Endocrinol Metab 2014; 28:481–494.
Gerber D. [Thyroid weights and iodized salt prophylaxis: a comparative study from autopsy material from the Institute of Pathology, University of Zurich]. Schweiz Med Wochenschr 1980; 110:2010–2017.
Matovinovic J. Endemic goiter and cretinism at the dawn of the third millennium. Annu Rev Nutr 1983; 3:341–412.
Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955; 15:1270–1280.
Pankow BG, Michalak J, McGee MK. Adult human thyroid weight. Health Phys 1985; 49:1097–1103.
Langer P. Minireview: discussion about the limit between normal thyroid goiter. Endocr Regul 1999; 33:39–45.
Derwahl M, Studer H. Nodular goiter and goiter nodules: where iodine deficiency falls short of explaining the facts. Exp Clin Endocrinol Diabetes 2001; 109:250–260.
Pearce EN, Andersson M, Zimmermann MB. Global iodine nutrition: where do we stand in 2013? Thyroid 2013; 23:523–528.
Carle A, Krejbjerg A, Laurberg P. Epidemiology of nodular goitre. Influence of iodine intake. Best Pract Res Clin Endocrinol Metab 2014; 28:465–479.
Krohn K, Führer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005; 26:504–524.
Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337:1675–1681.
Krohn K, Paschke R. Clinical review 133: progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab 2001; 86:3336–3345.
Medeiros-Neto G, Camargo RY, Tomimori EK. Approach to and treatment of goiters. Med Clin North Am 2012; 96:351–368.
Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24:102–132.
Duprez L, Parma J, Van Sande J, et al. Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994; 7:396–401.
White ML, Doherty GM, Gauger PG. Evidence-based surgical management of substernal goiter. World J Surg 2008; 32:1285–1300.
Shin JJ, Grillo HC, Mathisen D, et al. The surgical management of goiter: Part I. Preoperative evaluation. Laryngoscope 2011; 121:60–67.
Gutierrez T, Leong AC, Pang L, Chevretton E, Jeannon JP, Simo R. Multinodular thyroid goitre causing obstructive sleep apnoea syndrome. J Laryngol Otol 2012; 126:190–195.
Menon SK, Jagtap VS, Sarathi V, et al. Prevalence of upper airway obstruction in patients with apparently asymptomatic euthyroid multi nodular goitre. Indian J Endocrinol Metab 2011; 15: (suppl 2): S127–S131.
Thusoo TK, Gupta U, Kochhar K, Hira HS. Upper airway obstruction in patients with goiter studies by flow volume loops and effect of thyroidectomy. World J Surg 2000; 24:1570–1572.
Miller MR, Pincock AC, Oates GD, Wilkinson R, Skene-Smith H. Upper airway obstruction due to goitre: detection, prevalence and results of surgical management. Q J Med 1990; 74:177–188.
Jauregui R, Lilker ES, Bayley A. Upper airway obstruction in euthyroid goiter. JAMA 1977; 238:2163–2166.
Albareda M, Viguera J, Santiveri C, et al. Upper airway obstruction in patients with endothoracic goiter enlargement: no relationship between flow-volume loops and radiological tests. Eur J Endocrinol 2010; 163:665–669.
Arici C, Dertsiz L, Altunbas H, Demircan A, Emek K. Operative management of substernal goiter: analysis of 52 patients. Int Surg 2001; 86:220–224.
Parra-Membrives P, Sánchez-Blanco JM, Gómez-Rubio D, Recio-Moyano G, Diaz-Roldán J. Retrosternal goiters: safety of surgical treatment. Int Surg 2003; 88:205–210.
Erbil Y, Bozbora A, Barbaros U, Ozarmağan S, Azezli A, Molvalilar S. Surgical management of substernal goiters: clinical experience of 170 cases. Surg Today 2004; 34:732–736.
Pieracci FM, Fahey TJ 3rd. Substernal thyroidectomy is associated with increased morbidity and mortality as compared with conventional cervical thyroidectomy. J Am Coll Surg 2007; 205:1–7.
Pemberton HS. Sign of submerged goitre. Lancet 1946; 248:509.
Zhou H, McHenry CR, Pemberton HS, Surgical endocrinopathies: clinical management and the founding figures, ed. Pasieka JL and L JA 2015, Switzerland: Springer International Publishing.
Hintze G, Emrich D, Kobberling J. Treatment of endemic goitre due to iodine deficiency with iodine, levothyroxine or both: results of a multicentre trial. Eur J Clin Invest 1989; 19:527–534.
Grussendorf M, Reiners C, Paschke R, Wegscheider K. LISA Investigators. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2011; 96:2786–2795.
Koc M, Ersoz HO, Akpinar I, Gogas-Yavuz D, Deyneli O, Akalin S. Effect of low- and high-dose levothyroxine on thyroid nodule volume: a crossover placebo-controlled trial. Clin Endocrinol (Oxf) 2002; 57:621–628.
Berghout A, Wiersinga WM, Drexhage HA, Smits NJ, Touber JL. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet 1990; 336:193–197.
Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 2001; 86:998–1005.
Fast S, Bonnema SJ, Hegedus L. The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol (Oxf) 2008; 69:653–658.
Schneider R, Schneider M, Reiners C, Schneider P. Effects of levothyroxine on bone mineral density, muscle force, and bone turnover markers: a cohort study. J Clin Endocrinol Metab 2012; 97:3926–3934.
Hegedus L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab 1999; 84:756–760.
Fast S, Nielsen VE, Grupe P, et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab 2012; 97:2653–2660.
Nieuwlaat WA, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 2003; 88:3121–3129.
Huysmans DA, Huysmans DA, van den Bosch HC, et al. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter. J Clin Endocrinol Metab 2000; 85:3592–3596.
Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012; 33:920–980.
Cirocchi R, Trastulli S, Randolph J, et al. Total or near-total thyroidectomy versus subtotal thyroidectomy for multinodular non-toxic goitre in adults. Cochrane Database Syst Rev 2015; (8):CD010370.
Giles Y, Boztepe H, Terzioglu T, Tezelman S. The advantage of total thyroidectomy to avoid reoperation for incidental thyroid cancer in multinodular goiter. Arch Surg 2004; 139:179–182.
Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P. Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg 1998; 164:501–506.
Barczynski M, Konturek A, Hubalewska-Dydejczyk A, Gołkowski F, Cichoń S, Nowak W. Five-year follow-up of a randomized clinical trial of total thyroidectomy versus Dunhill operation versus bilateral subtotal thyroidectomy for multinodular nontoxic goiter. World J Surg 2010; 34:1203–1213.
Yang W, Shao T, Ding J, et al. The feasibility of total or near-total bilateral thyroidectomy for the treatment of bilateral multinodular goiter. J Invest Surg 2009; 22:195–200.
Phitayakorn R, Narendra D, Bell S, McHenry CR. What constitutes adequate surgical therapy for benign nodular goiter? J Surg Res 2009; 154:51–55.
Attaallah W, Erel S, Canturk NZ, et al. Is hemithyroidectomy a rational management for benign nodular goitre? A multicentre retrospective single group study. Neth J Med 2015; 73:17–22.
Lang BH, Chu KK, Tsang RK, Wong KP, Wong BY. Evaluating the incidence, clinical significance and predictors for vocal cord palsy and incidental laryngopharyngeal conditions before elective thyroidectomy: is there a case for routine laryngoscopic examination? World J Surg 2014; 38:385–391.
Netterville JL, Coleman SC, Smith JC, Smith MM, Day TA, Burkey BB. Management of substernal goiter. Laryngoscope 1998; 108 (1 pt 1):1611–1617.
Cooper JC, Nakielny R, Talbot CH. The use of computed tomography in the evaluation of large multinodular goitres. Ann R Coll Surg Engl 1991; 73:32–35.
Tsilimigras DI, Patrini D, Antonopoulou A, et al. Retrosternal goitre: the role of the thoracic surgeon. J Thorac Dis 2017; 9:860–863.
Mercante G, Gabrielli E, Pedroni C, et al. CT cross-sectional imaging classification system for substernal goiter based on risk factors for an extracervical surgical approach. Head Neck 2011; 33:792–799.
Pieracci FM, Fahey TJ 3rd. Effect of hospital volume of thyroidectomies on outcomes following substernal thyroidectomy. World J Surg 2008; 32:740–746.
Agarwal A, Agarwal S, Tewari P, et al. Clinicopathological profile, airway management, and outcome in huge multinodular goiters: an institutional experience from an endemic goiter region. World J Surg 2012; 36:755–760.
Gilfillan N, Ball CM, Myles PS, Serpell J, Johnson WR, Paul E. A cohort and database study of airway management in patients undergoing thyroidectomy for retrosternal goitre. Anaesth Intensive Care 2014; 42:700–708.
Randolph GW, Dralle H, International Intraoperative Monitoring Study Group, et al. Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. Laryngoscope 2011; 121: (suppl 1): S1–16.
Samraj K, Gurusamy KS. Wound drains following thyroid surgery. Cochrane Database Syst Rev 2007; (4):CD006099.
Tian J, Li L, Liu P, Wang X. Comparison of drain versus no-drain thyroidectomy: a meta-analysis. Eur Arch Otorhinolaryngol 2017; 274:567–577.
Moten AS, Thibault DP, Willis AW, Willis AI. Demographics, disparities, and outcomes in substernal goiters in the United States. Am J Surg 2016; 211:703–709.
Findlay JM, Sadler GP, Bridge H, Mihai R. Post-thyroidectomy tracheomalacia: minimal risk despite significant tracheal compression. Br J Anaesth 2011; 106:903–906.
Chi SY, Wu SC, Hsieh KC, Sheen-Chen SM, Chou FF. Noninvasive positive pressure ventilation in the management of post-thyroidectomy tracheomalacia. World J Surg 2011; 35:1977–1983.
Kirdak T, Korun N, Ozguc H. Use of ligasure in thyroidectomy procedures: results of a prospective comparative study. World J Surg 2005; 29:771–774.
Saint Marc O, Cogliandolo A, Piquard A, Famà F, Pidoto RR. LigaSure vs clamp-and-tie technique to achieve hemostasis in total thyroidectomy for benign multinodular goiter: a prospective randomized study. Arch Surg 2007; 142:150–156.
Yao HS, Wang Q, Wang WJ, Ruan CP. Prospective clinical trials of thyroidectomy with LigaSure vs conventional vessel ligation: a systematic review and meta-analysis. Arch Surg 2009; 144:1167–1174.
Singh P, O’Connell D, Langille M, Dziegielewski P, Allegretto M, Harris J. LigaSure versus conventional hemostasis in thyroid surgery: prospective randomized controlled trial. J Otolaryngol Head Neck Surg 2010; 39:378–384.
Schiphorst AH, Twigt BA, Elias SG, van Dalen T. Randomized clinical trial of LigaSure versus conventional suture ligation in thyroid surgery. Head Neck Oncol 2012; 4:2.
Glover AR, Gundara JS, Lee JC, Sywak MS, Delbridge LW, Sidhu SB. Thermal sealing systems with and without tissue divider for total thyroidectomy. ANZ J Surg 2014; 84:383–385.
Cordon C, Cordón C, Fajardo R, Ramírez J, Herrera MF. A randomized, prospective, parallel group study comparing the Harmonic Scalpel to electrocautery in thyroidectomy. Surgery 2005; 137:337–341.
Miccoli P, Berti P, Dionigi GL, et al. Randomized controlled trial of harmonic scalpel use during thyroidectomy. Arch Otolaryngol Head Neck Surg 2006; 132:1069–1073.
Kang SK, Kunanandam T, Clark L. Prospective, case-control study of surgical efficiency of ultrasonic shear (‘harmonic scalpel’) thyroidectomy compared with conventional thyroidectomy. J Laryngol Otol 2008; 122:1194–1196.
Koh YW, Park JH, Lee SW, Choi EC. The harmonic scalpel technique without supplementary ligation in total thyroidectomy with central neck dissection: a prospective randomized study. Ann Surg 2008; 247:945–949.
Lombardi CP, Raffaelli M, Cicchetti A, et al. The use of “harmonic scalpel” versus “knot tying” for conventional “open” thyroidectomy: results of a prospective randomized study. Langenbecks Arch Surg 2008; 393:627–631.
Duan YF, Xue W, Zhu F, Sun DL. FOCUS harmonic scalpel compared to conventional hemostasis in open total thyroidectomy: a prospective randomized study. J Otolaryngol Head Neck Surg 2013; 42:62.
Zanghi A, Cavallaro A, Di Vita M, et al. The safety of the Harmonic(R) FOCUS in open thyroidectomy: a prospective, randomized study comparing the Harmonic(R) FOCUS and traditional suture ligation (knot and tie) technique. Int J Surg 2014; 12: (suppl 1): S132–S135.
Sartori PV, De Fina S, Colombo G, et al. Ligasure versus Ultracision in thyroid surgery: a prospective randomized study. Langenbecks Arch Surg 2008; 393:655–658.
Pons Y, Gauthier J, Ukkola-Pons E, et al. Comparison of LigaSure vessel sealing system, harmonic scalpel, and conventional hemostasis in total thyroidectomy. Otolaryngol Head Neck Surg 2009; 141:496–501.
Rahbari R, Mathur A, Kitano M, et al. Prospective randomized trial of ligasure versus harmonic hemostasis technique in thyroidectomy. Ann Surg Oncol 2011; 18:1023–1027.
Dionigi G, Boni L, Rausei S, et al. The safety of energy-based devices in open thyroidectomy: a prospective, randomised study comparing the LigaSure (LF1212) and the Harmonic(R) FOCUS. Langenbecks Arch Surg 2012; 397:817–823.
Kwak HY, Chae BJ, Park YG, et al. Comparison of surgical outcomes between papillary thyroid cancer patients treated with the Harmonic ACE scalpel and LigaSure Precise instrument during conventional thyroidectomy: a single-blind prospective randomized controlled trial. J Surg Res 2014; 187:484–489.
Hwang SO, Jung JH, Park HY, Kim WW. A prospective, randomized study between the small Jaw(R) and the harmonic Focus(R) in open thyroidectomy. Otolaryngol Head Neck Surg 2014; 150:943–948.
Garas G, Okabayashi K, Ashrafian H, et al. Which hemostatic device in thyroid surgery? A network meta-analysis of surgical technologies. Thyroid 2013; 23:1138–1150.
Contin P, Gooßen K, Grummich K, et al. ENERgized vessel sealing systems versus CONventional hemostasis techniques in thyroid surgery—the ENERCON systematic review and network meta-analysis. Langenbecks Arch Surg 2013; 398:1039–1056.
Lo CY, Kwok KF, Yuen PW. A prospective evaluation of recurrent laryngeal nerve paralysis during thyroidectomy. Arch Surg 2000; 135:204–207.
Chan WF, Lang BH, Lo CY. The role of intraoperative neuromonitoring of recurrent laryngeal nerve during thyroidectomy: a comparative study on 1000 nerves at risk. Surgery 2006; 140:866–872.
Shindo M, Chheda NN. Incidence of vocal cord paralysis with and without recurrent laryngeal nerve monitoring during thyroidectomy. Arch Otolaryngol Head Neck Surg 2007; 133:481–485.
Dralle H, Sekulla C, Lorenz K, et al. Intraoperative monitoring of the recurrent laryngeal nerve in thyroid surgery. World J Surg 2008; 32:1358–1366.
Alesina PF, Rolfs T, Hommeltenberg S, et al. Intraoperative neuromonitoring does not reduce the incidence of recurrent laryngeal nerve palsy in thyroid reoperations: results of a retrospective comparative analysis. World J Surg 2012; 36:1348–1353.
Cavicchi O, Caliceti U, Fernandez IJ, et al. Laryngeal neuromonitoring and neurostimulation versus neurostimulation alone in thyroid surgery: a randomized clinical trial. Head Neck 2012; 34:141–145.
Pisanu A, Porceddu G, Podda M, Cois A, Uccheddu A. Systematic review with meta-analysis of studies comparing intraoperative neuromonitoring of recurrent laryngeal nerves versus visualization alone during thyroidectomy. J Surg Res 2014; 188:152–161.
Calò PG, Pisano G, Medas F, et al. Identification alone versus intraoperative neuromonitoring of the recurrent laryngeal nerve during thyroid surgery: experience of 2034 consecutive patients. J Otolaryngol Head Neck Surg 2014; 43:16.
Mirallié É, Caillard C, Pattou F, et al. Does intraoperative neuromonitoring of recurrent nerves have an impact on the postoperative palsy rate? Results of a prospective multicenter study. Surgery 2018; 163:124–129.
Henry BM, Graves MJ, Vikse J, et al. The current state of intermittent intraoperative neural monitoring for prevention of recurrent laryngeal nerve injury during thyroidectomy: a PRISMA-compliant systematic review of overlapping meta-analyses. Langenbecks Arch Surg 2017; 402:663–673.
Rocke DJ, Goldstein DP, de Almeida JR. A cost-utility analysis of recurrent laryngeal nerve monitoring in the setting of total thyroidectomy. JAMA Otolaryngol Head Neck Surg 2016; 142:1199–1205.
Al-Qurayshi Z, Kandil E, Randolph GW. Cost-effectiveness of intraoperative nerve monitoring in avoidance of bilateral recurrent laryngeal nerve injury in patients undergoing total thyroidectomy. Br J Surg 2017; 104:1523–1531.
Wong KP, Mak KL, Wong CK, Lang BH. Systematic review and meta-analysis on intra-operative neuro-monitoring in high-risk thyroidectomy. Int J Surg 2017; 38:21–30.
Wojtczak B, Kaliszewski K, Sutkowski K, Głód M, Barczyński M. The learning curve for intraoperative neuromonitoring of the recurrent laryngeal nerve in thyroid surgery. Langenbecks Arch Surg 2017; 402:701–708.
Dionigi G, Frattini F. Staged thyroidectomy: time to consider intraoperative neuromonitoring as standard of care. Thyroid 2013; 23:906–908.
Fontenot TE, Randolph GW, Setton TE, Alsaleh N, Kandil E. Does intraoperative nerve monitoring reliably aid in staging of total thyroidectomies? Laryngoscope 2015; 125:2232–2235.
Schneider R, Randolph GW, Dionigi G, et al. International neural monitoring study group guideline 2018 part I: staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope 2018; 128: (suppl 3): S1–S17.
Wu CW, Dionigi G, Barczynski M, et al. International neuromonitoring study group guidelines 2018: Part II: optimal recurrent laryngeal nerve management for invasive thyroid cancer-incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope 2018; 128: (suppl 3): S18–S27.
Stopa M, Barczynski M. Prognostic value of intraoperative neural monitoring of the recurrent laryngeal nerve in thyroid surgery. Langenbecks Arch Surg 2017; 402:957–964.
Koulouris C, Papavramidis TS, Pliakos I, et al. Intraoperative stimulation neuromonitoring versus intraoperative continuous electromyographic neuromonitoring in total thyroidectomy: identifying laryngeal complications. Am J Surg 2012; 204:49–53.
Schneider R, Randolph GW, Sekulla C, et al. Continuous intraoperative vagus nerve stimulation for identification of imminent recurrent laryngeal nerve injury. Head Neck 2013; 35:1591–1598.
Phelan E, Schneider R, Lorenz K, et al. Continuous vagal IONM prevents recurrent laryngeal nerve paralysis by revealing initial EMG changes of impending neuropraxic injury: a prospective, multicenter study. Laryngoscope 2014; 124:1498–1505.
Dionigi G, Chiang FY, Hui S, et al. Continuous Intraoperative Neuromonitoring (C-IONM) Technique with the Automatic Periodic Stimulating (APS) Accessory for Conventional and Endoscopic Thyroid Surgery. Surg Technol Int 2015; 26:101–114.
Kandil E, Mohsin K, Murcy MA, Randolph GW. Continuous vagal monitoring value in prevention of vocal cord paralysis following thyroid surgery. Laryngoscope 2018; 128:2429–2432.
Marin Arteaga A, Peloni G, Leuchter I, et al. Modification of the surgical strategy for the dissection of the recurrent laryngeal nerve using continuous intraoperative nerve monitoring. World J Surg 2018; 42:444–450.
Terris DJ, Chaung K, Duke WS. Continuous vagal nerve monitoring is dangerous and should not routinely be done during thyroid surgery. World J Surg 2015; 39:2471–2476.
Barczynski M, Barczyński M, Konturek A, Stopa M, Honowska A, Nowak W. Randomized controlled trial of visualization versus neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy. World J Surg 2012; 36:1340–1347.
Glover AR, Norlén O, Gundara JS, Morris M, Sidhu SB. Use of the nerve integrity monitor during thyroid surgery aids identification of the external branch of the superior laryngeal nerve. Ann Surg Oncol 2015; 22:1768–1773.
Kandil E, Mohamed SE, Deniwar A, et al. Electrophysiologic identification and monitoring of the external branch of superior laryngeal nerve during thyroidectomy. Laryngoscope 2015; 125:1996–2000.
Masuoka H, Miyauchi A, Higashiyama T, et al. Prospective randomized study on injury of the external branch of the superior laryngeal nerve during thyroidectomy comparing intraoperative nerve monitoring and a conventional technique. Head Neck 2015; 37:1456–1460.
Lo CY, Luk JM, Tam SC. Applicability of intraoperative parathyroid hormone assay during thyroidectomy. Ann Surg 2002; 236:564–569.
Richards ML, Bingener-Casey J, Pierce D, Strodel WE, Sirinek KR. Intraoperative parathyroid hormone assay: an accurate predictor of symptomatic hypocalcemia following thyroidectomy. Arch Surg 2003; 138:632–635.
Higgins KM, Mandell DL, Govindaraj S, et al. The role of intraoperative rapid parathyroid hormone monitoring for predicting thyroidectomy-related hypocalcemia. Arch Otolaryngol Head Neck Surg 2004; 130:63–67.
Quiros RM, Pesce CE, Wilhelm SM, Djuricin G, Prinz RA. Intraoperative parathyroid hormone levels in thyroid surgery are predictive of postoperative hypoparathyroidism and need for vitamin D supplementation. Am J Surg 2005; 189:306–309.
Di Fabio F, Casella C, Bugari G, Iacobello C, Salerni B. Identification of patients at low risk for thyroidectomy-related hypocalcemia by intraoperative quick PTH. World J Surg 2006; 30:1428–1433.
McLeod IK, Arciero C, Noordzij JP, et al. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid 2006; 16:259–265.
Barczynski M, Cichon S, Konturek A. Which criterion of intraoperative iPTH assay is the most accurate in prediction of true serum calcium levels after thyroid surgery? Langenbecks Arch Surg 2007; 392:693–698.
Lang BH, Yih PC, Ng KK. A prospective evaluation of quick intraoperative parathyroid hormone assay at the time of skin closure in predicting clinically relevant hypocalcemia after thyroidectomy. World J Surg 2012; 36:1300–1306.
Gupta S, Chaudhary P, Durga CK, Naskar D, et al. Validation of intra-operative parathyroid hormone and its decline as early predictors of hypoparathyroidism after total thyroidectomy: a prospective cohort study. Int J Surg 2015; 18:150–153.
Reddy AC, Chand G, Sabaretnam M, et al. Prospective evaluation of intra-operative quick parathyroid hormone assay as an early predictor of post thyroidectomy hypocalcaemia. Int J Surg 2016; 34:103–108.
Lee DR, Hinson AM, Siegel ER, Steelman SC, Bodenner DL, Stack BC Jr. Comparison of intraoperative versus postoperative parathyroid hormone levels to predict hypocalcemia earlier after total thyroidectomy. Otolaryngol Head Neck Surg 2015; 153:343–349.
De Leeuw F, Breuskin I, Abbaci M, et al. Intraoperative near-infrared imaging for parathyroid gland identification by auto-fluorescence: a feasibility study. World J Surg 2016; 40:2131–2138.
Kim SW, Song SH, Lee HS, et al. Intraoperative real-time localization of normal parathyroid glands with autofluorescence imaging. J Clin Endocrinol Metab 2016; 101:4646–4652.
McWade MA, Sanders ME, Broome JT, Solórzano CC, Mahadevan-Jansen A. Establishing the clinical utility of autofluorescence spectroscopy for parathyroid detection. Surgery 2016; 159:193–202.
Vidal Fortuny J, Belfontali V, Sadowski SM, Karenovics W, Guigard S, Triponez F. Parathyroid gland angiography with indocyanine green fluorescence to predict parathyroid function after thyroid surgery. Br J Surg 2016; 103:537–543.
Zaidi N, Bucak E, Yazici P, et al. The feasibility of indocyanine green fluorescence imaging for identifying and assessing the perfusion of parathyroid glands during total thyroidectomy. J Surg Oncol 2016; 113:775–778.
Lang BH, Wong CK, Hung HT, Wong KP, Mak KL, Au KB. Indocyanine green fluorescence angiography for quantitative evaluation of in situ parathyroid gland perfusion and function after total thyroidectomy. Surgery 2017; 161:87–95.
Kahramangil B, Dip F, Benmiloud F, et al. Detection of parathyroid autofluorescence using near-infrared imaging: a multicenter analysis of concordance between different surgeons. Ann Surg Oncol 2018; 25:957–962.
Kim MJ, Nam KH, Lee SG, et al. Yonsei experience of 5000 gasless transaxillary robotic thyroidectomies. World J Surg 2018; 42:393–401.
Lang BH, Wong CK, Tsang JS, Wong KP. A systematic review and meta-analysis comparing outcomes between robotic-assisted thyroidectomy and non-robotic endoscopic thyroidectomy. J Surg Res 2014; 191:389–398.
Choi JY, Lee KE, Chung KW, et al. Endoscopic thyroidectomy via bilateral axillo-breast approach (BABA): review of 512 cases in a single institute. Surg Endosc 2012; 26:948–955.
Lee KE, Kim E, Koo do H, Choi JY, Kim KH, Youn YK. Robotic thyroidectomy by bilateral axillo-breast approach: review of 1,026 cases and surgical completeness. Surg Endosc 2013; 27:2955–2962.
Berber E, Bernet V, Fahey TJ 3rd, et al. American Thyroid Association statement on remote-access thyroid surgery. Thyroid 2016; 26:331–337.
Anuwong A. Transoral endoscopic thyroidectomy vestibular approach: a series of the first 60 human cases. World J Surg 2016; 40:491–497.
Arviso LC, Johns MM 3rd, Mathison CC, Klein AM. Long-term outcomes of injection laryngoplasty in patients with potentially recoverable vocal fold paralysis. Laryngoscope 2010; 120:2237–2240.
Adam MA, Speicher P, Pura J, et al. Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes. Ann Surg Oncol 2014; 21:3859–3864.
Lang BH, Ng SH, Lau LL, Cowling BJ, Wong KP. A systematic review and meta-analysis comparing the efficacy and surgical outcomes of total thyroidectomy between harmonic scalpel versus ligasure. Ann Surg Oncol 2013; 20:1918–1926.
Landry CS, Grubbs EG, Morris GS, et al. Robot assisted transaxillary surgery (RATS) for the removal of thyroid and parathyroid glands. Surgery 2011; 149:549–555.
Amit M, Binenbaum Y, Cohen JT, Gil Z. Effectiveness of an oxidized cellulose patch hemostatic agent in thyroid surgery: a prospective, randomized, controlled study. J Am Coll Surg 2013; 217:221–225.
Testini M, Marzaioli R, Lissidini G, et al. The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg 2009; 394:837–842.
Docimo G, Tolone S, Conzo G, et al. A Gelatin-Thrombin Matrix Topical Hemostatic Agent (Floseal) in combination with harmonic scalpel is effective in patients undergoing total thyroidectomy: a prospective, multicenter, single-blind, randomized controlled trial. Surg Innov 2016; 23:23–29.
Uwiera TC, Uwiera RR, Seikaly H, Harris JR. Tisseel and its effects on wound drainage post-thyroidectomy: prospective, randomized, blinded, controlled study. J Otolaryngol 2005; 34:374–378.
Snyder SK, Angelos P, Carty SE, et al. Injection of bulking agents for laryngoplasty. Surgery 2018; 163:6–8.
Jeannon JP, Orabi AA, Bruch GA, Abdalsalam HA, Simo R. Diagnosis of recurrent laryngeal nerve palsy after thyroidectomy: a systematic review. Int J Clin Pract 2009; 63:624–629.
Papaleontiou M, Hughes DT, Guo C, Banerjee M, Haymart MR. Population-based assessment of complications following surgery for thyroid cancer. J Clin Endocrinol Metab 2017.
Kikura M, Suzuki K, Itagaki T, Takada T, Sato S. Age and comorbidity as risk factors for vocal cord paralysis associated with tracheal intubation. Br J Anaesthesia 2007; 98:524–530.
Gardner GM, Smith MM, Yaremchuk KL, Peterson EL. The cost of vocal fold paralysis after thyroidectomy. Laryngoscope 2013; 123:1455–1463.
Fundakowski CE, Hales NW, Agrawal N, et al. Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. Head Neck 2018; 40:663–675.
Hodin R, Clark O, Doherty G, Grant C, Heller K, Weigel R. Voice issues and laryngoscopy in thyroid surgery patients. Surgery 2013; 154:46–47.
Sinclair CF, Bumpous JM, Haugen BR, et al. Laryngeal examination in thyroid and parathyroid surgery: an American Head and Neck Society consensus statement: AHNS Consensus Statement. Head Neck 2016; 38:811–819.
Lee CY, Long KL, Eldridge RJ, Davenport DL, Sloan DA. Preoperative laryngoscopy in thyroid surgery: Do patients’ subjective voice complaints matter? Surgery 2014; 156:1477–1482.
Bergenfelz A, Jansson S, Kristoffersson A, et al. Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch Surg 2008; 393:667–673.
Maniakas A, Christopoulos A, Bissada E, et al. Perioperative practices in thyroid surgery: an international survey. Head Neck 2017; 39:1296–1305.
Scott-Coombes, D. The British Association of Endocrine and Thyroid Surgeons – Third National Audit Report.
Shaha AR. Editorial: laryngeal evaluation for thyroid surgery: back to the basics. Surgery 2016; 159:65–66.
Xin J, Liu X, Sun H, Li J, Zhang D, Fu Y. A laryngoscopy-based classification system for perioperative abnormal vocal cord movement in thyroid surgery. J Int Med Res 2014; 42:1029–1037.
Speyer R, Bogaardt HC, Passos VL, et al. Maximum phonation time: variability and reliability. J Voice 2010; 24:281–284.
Kempster GB, Gerratt BR, Verdolini Abbott K, Barkmeier-Kraemer J, Hillman RE. Consensus auditory-perceptual evaluation of voice: development of a standardized clinical protocol. Am J Speech Lang Pathol 2009; 18:124–132.
Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI): Development and Validation. Am J Speech-Lang Pathol 1997; 6:66–70.
Hirano, M, ed. Clinical Examination of Voice. New York: Springer Verlag; 1981:81–4.
Dejonckere, GRBAS-scaling of pathological voices: reliability, clinical relevance and differentiated correlation with acoustic measurements, especially with cepstral measurements. Proceedings of the 22nd IALP Congress, Hanover, Germany, 1992.
Hirano, M. Clinical applications of voice tests, assessment of speech and voice production: research and clinical applications. NIDCD monograph in Proceedings of a conference of the National Institute of Health. 1990. Bethesda, MD.
Franch-Arcas G, González-Sánchez C, Aguilera-Molina YY, et al. Is there a case for selective, rather than routine, preoperative laryngoscopy in thyroid surgery? Gland Surg 2015; 4:8–18.
Lang BH, Wong CK, Tsang RK, Wong KP, Wong BY. Evaluating the cost-effectiveness of laryngeal examination after elective total thyroidectomy. Ann Surg Oncol 2014; 21:3548–3556.
Kay-Rivest E, Mitmaker E, Payne RJ, et al. Preoperative vocal cord paralysis and its association with malignant thyroid disease and other pathological features. J Otolaryngol Head Neck Surg 2015; 44:35.
Wang CC, Wang CP, Tsai TL, et al. The basis of preoperative vocal fold paralysis in a series of patients undergoing thyroid surgery: the preponderance of benign thyroid disease. Thyroid 2011; 21:867–872.
Cheng SP, Lee JJ, Liu TP, Lee KS, Liu CL. Preoperative ultrasonography assessment of vocal cord movement during thyroid and parathyroid surgery. World J Surg 2012; 36:2509–2515.
Green KM, de Carpentier JP. Are pre-operative vocal fold checks necessary? J Laryngol Otol 1999; 113:642–644.
Rowe-Jones JM, Rosswick RP, Leighton SE. Benign thyroid disease and vocal cord palsy. Ann R Coll Surg Engl 1993; 75:241–244.
de Pedro Netto I, Fae A, Vartanian JG, et al. Voice and vocal self-assessment after thyroidectomy. Head Neck 2006; 28:1106–1114.
Musholt TJ, Musholt PB, Garm J, et al. Changes of the speaking and singing voice after thyroid or parathyroid surgery. Surgery 2006; 140:978–988.
Page C, Zaatar R, Biet A, Strunski V. Subjective voice assessment after thyroid surgery: a prospective study of 395 patients. Indian J Med Sci 2007; 61:448–454.
Rosato L, Carlevato MT, De Toma G, Avenia N. Recurrent laryngeal nerve damage and phonetic modifications after total thyroidectomy: surgical malpractice only or predictable sequence? World J Surg 2005; 29:780–784.
Sinagra DL, Montesinos MR, Tacchi VA, et al. Voice changes after thyroidectomy without recurrent laryngeal nerve injury. J Am Coll Surg 2004; 199:556–560.
Stojadinovic A, Shaha AR, Orlikoff RF, et al. Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg 2002; 236:823–832.
Mendels EJ, Brunings JW, Hamaekers AE, Stokroos RJ, Kremer B, Baijens LW. Adverse laryngeal effects following short-term general anesthesia: a systematic review. Arch Otolaryngol Head Neck Surg 2012; 138:257–264.
Friedman AD, Burns JA, Heaton JT, Zeitels SM. Early versus late injection medialization for unilateral vocal cord paralysis. Laryngoscope 2010; 120:2042–2046.
Yung KC, Likhterov I, Courey MS. Effect of temporary vocal fold injection medialization on the rate of permanent medialization laryngoplasty in unilateral vocal fold paralysis patients. Laryngoscope 2011; 121:2191–2194.
Mattsson P, Frostell A, Björck G, et al. Recovery of voice after reconstruction of the recurrent laryngeal nerve and adjuvant nimodipine. World J Surg 2018; 42:632–638.
Rosen CA, Smith L, Young V, Krishna P, Muldoon MF, Munin MC. Prospective investigation of nimodipine for acute vocal fold paralysis. Muscle Nerve 2014; 50:114–118.
Sridharan SS, Rosen CA, Smith LJ, Young VN, Munin MC. Timing of nimodipine therapy for the treatment of vocal fold paralysis. Laryngoscope 2015; 125:186–190.
Orestes MI, Chhetri DK. Superior laryngeal nerve injury: effects, clinical findings, prognosis, and management options. Curr Opin Otolaryngol Head Neck Surg 2014; 22:439–443.
Fuller DR, JP, Peregoy BM. Applied Anatomy & Physiology for Speech-Language Pathology & Audiology. Baltimore, MD: Wolters Kluwer- Lippincott Williams & Wilkins; 2012.
Potenza AS, Araujo Filho VJF, Cernea CR. Injury of the external branch of the superior laryngeal nerve in thyroid surgery. Gland Surg 2017; 6:552–562.
Mcivor NP, Flint DJ, Gillibrand J, Morton RP. Thyroid surgery and voice-related outcomes. Aust N Z J Surg 2000; 70:179–183.
Gourin CG and Eisele DW. CHAPTER 39 - Complications of Thyroid Surgery, in Complications in Head and Neck Surgery. 2nd ed. Philadelphia, PA: Mosby; 2009:493–515.
Cernea CR, Ferraz AR, Furlani J, et al. Identification of the external branch of the superior laryngeal nerve during thyroidectomy. Am J Surg 1992; 164:634–639.
Cernea CR, Nishio S, Hojaij FC. Identification of the external branch of the superior laryngeal nerve (EBSLN) in large goiters. Am J Otolaryngol 1995; 16:307–311.
Loré JM Jr, Kokocharov SI, Kaufman S, Richmond A, Sundquist N. Thirty-eight-year evaluation of a surgical technique to protect the external branch of the superior laryngeal nerve during thyroidectomy. Ann Otol Rhinol Laryngol 1998; 107:1015–1022.
Jansson S, Tisell LE, Hagne I, Sanner E, Stenborg R, Svensson P. Partial superior laryngeal nerve (SLN) lesions before and after thyroid surgery. World J Surg 1988; 12:522–527.
Barczyński M, Randolph GW, Cernea CR, et al. External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. Laryngoscope 2013; 123: (suppl 4): S1–S14.
Genther DJ, Kandil EH, Noureldine SI, Tufano RP. Correlation of final evoked potential amplitudes on intraoperative electromyography of the recurrent laryngeal nerve with immediate postoperative vocal fold function after thyroid and parathyroid surgery. JAMA Otolaryngol Head Neck Surg 2014; 140:124–128.
Gohrbandt AE, Aschoff A, Gohrbandt B, et al. Changes of laryngeal mobility and symptoms following thyroid surgery: 6-month follow-up. World J Surg 2016; 40:636–643.
Henry LR, Abad JD, Stojadinovic A. The voice, not the nerve, is the functionally relevant endpoint. J Surg Oncol 2012; 106:1005–1006.
Lorenz K, Abuazab M, Sekulla C, et al. Results of intraoperative neuromonitoring in thyroid surgery and preoperative vocal cord paralysis. World J Surg 2014; 38:582–591.
Melin M, Schwarz K, Pearson MD, Lammers BJ, Goretzki PE. Postoperative vocal cord dysfunction despite normal intraoperative neuromonitoring: an unexpected complication with the risk of bilateral palsy. World J Surg 2014; 38:2597–2602.
Shonka DC Jr, Terris DJ. The American Thyroid Association Guidelines on Voice Assessment-Have We Done Enough? JAMA Otolaryngol Head Neck Surg 2016; 142:115–116.
Stopa M, Barczyński M. Prognostic value of intraoperative neural monitoring of the recurrent laryngeal nerve in thyroid surgery. Langenbecks Arch Surg 2017; 402:957–964.
Vicente DA, Solomon NP, Avital I, et al. Voice outcomes after total thyroidectomy, partial thyroidectomy, or non-neck surgery using a prospective multifactorial assessment. J Am Coll Surg 2014; 219:152–163.
Martinez ARM, Martins MP, Moreira AL, et al. Electrophysiology of cranial nerve testing: cranial nerves IX and X. J Clin Neurophysiol 2018; 35:48–58.
Sinagra DL, Montesinos MR, Tacchi VA, et al. Voice changes after thyroidectomy without recurrent laryngeal nerve injury. J Am Coll Surg. 2004; 199: 556–560.
Kaneko M, Hitomi T, Takekawa T, Tsuji T, Kishimoto Y, Hirano S. Effects of voice therapy on laryngeal motor units during phonation in chronic superior laryngeal nerve paresis dysphonia. J Voice 2018; 32:729–733.
Steurer M, Passler C, Denk DM, Schneider B, Niederle B, Bigenzahn W. Advantages of recurrent laryngeal nerve identification in thyroidectomy and parathyroidectomy and the importance of preoperative and postoperative laryngoscopic examination in more than 1000 nerves at risk. Laryngoscope 2002; 112:124–133.
Bergenfelz A, Salem AF, Jacobsson H, et al. Risk of recurrent laryngeal nerve palsy in patients undergoing thyroidectomy with and without intraoperative nerve monitoring. Br J Surg 2016; 103:1828–1838.
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013; 13:184–199.
Peiling Yang S, Ngeow J. Familial non-medullary thyroid cancer: unraveling the genetic maze. Endocr Relat Cancer 2016; 23:R577–R595.
Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid 1997; 7:107–113.
Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid 2009; 19:1343–1349.
Moses W, Weng J, Kebebew E. Prevalence, clinicopathologic features, and somatic genetic mutation profile in familial versus sporadic nonmedullary thyroid cancer. Thyroid 2011; 21:367–371.
Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 2015; 33:3660–3667.
Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014; 32:2001–2009.
Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015; 121:25–33.
Plon SE, Cooper HP, Parks B, et al. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 2011; 13:148–154.
Charkes ND. On the prevalence of familial nonmedullary thyroid cancer in multiply affected kindreds. Thyroid 2006; 16:181–186.
Nixon IJ, Suárez C, Simo R, et al. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol 2016; 42:1455–1463.
He H, Bronisz A, Liyanarachchi S, et al. SRGAP1 is a candidate gene for papillary thyroid carcinoma susceptibility. J Clin Endocrinol Metab 2013; 98:E973–E980.
Ngan ES, Lang BH, Liu T, et al. A germline mutation (A339 V) in thyroid transcription factor-1 (TITF-1/NKX2.1) in patients with multinodular goiter and papillary thyroid carcinoma. J Natl Cancer Inst 2009; 101:162–175.
Pereira JS, da Silva JG, Tomaz RA, et al. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Endocrine 2015; 49:204–214.
Capezzone M, Cantara S, Marchisotta S, et al. Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients. J Clin Endocrinol Metab 2008; 93:3950–3957.
Liu C, Yu Y, Yin G, et al. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer. Biochem Biophys Res Commun 2017; 482:590–596.
Canzian F, Amati P, Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet 1998; 63:1743–1748.
McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet 2001; 69:440–446.
Malchoff CD, Sarfarazi M, Tendler B, et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000; 85:1758–1764.
Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet 1997; 61:1123–1130.
Cavaco BM, Batista PF, Sobrinho LG, Leite V. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. J Clin Endocrinol Metab 2008; 93:4426–4430.
Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Lacerda RX, Calsolari MR. Ultrasonographic screening for thyroid cancer in siblings of patients with apparently sporadic papillary carcinoma. Thyroid 2012; 22:805–808.
Uchino S, Noguchi S, Yamashita H, et al. Detection of asymptomatic differentiated thyroid carcinoma by neck ultrasonographic screening for familial nonmedullary thyroid carcinoma. World J Surg 2004; 28:1099–1102.
Maxwell EL, Hall FT, Freeman JL. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope 2004; 114:2182–2186.
Robenshtok E, Tzvetov G, Grozinsky-Glasberg S, et al. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study. Thyroid 2011; 21:43–48.
Wang X, Cheng W, Li J, et al. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. Eur J Endocrinol 2015; 172:R253–R262.
Hillenbrand A, Varhaug JE, Brauckhoff M, et al. Familial nonmedullary thyroid carcinoma-clinical relevance and prognosis. A European multicenter study. ESES Vienna presentation. Langenbecks Arch Surg 2010; 395:851–858.
Capezzone M, Marchisotta S, Cantara S, et al. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer 2008; 15:1075–1081.
Klubo-Gwiezdzinska J, Yang L, Merkel R, et al. Results of screening in familial non-medullary thyroid cancer. Thyroid 2017; 27:1017–1024.
Bauer AJ. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer. Front Horm Res 2013; 41:141–148.
Perrier ND, van Heerden JA, Goellner JR, et al. Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 1998; 22:738–742.
Cetta F, Ugolini G, Martellucci J, Gotti G. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2015; 261:e13–e14.
Jarrar AM, Milas M, Mitchell J, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011; 253:515–521.
Herraiz M, Barbesino G, Faquin W, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007; 5:367–373.
Bulow S, Holm NV, Mellemgaard A. Papillary thyroid carcinoma in Danish patients with familial adenomatous polyposis. Int J Colorectal Dis 1988; 3:29–31.
Bulow C, Bulow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 1997; 12:240–242.
Plail RO, Bussey HJ, Glazer G, Thomson JP. Adenomatous polyposis: an association with carcinoma of the thyroid. Br J Surg 1987; 74:377–380.
Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993; 34:1394–1396.
Tomoda C, Miyauchi A, Uruno T, et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg 2004; 28:886–889.
Nelen MR, Padberg GW, Peeters EA, et al. Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet 1996; 13:114–116.
Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41:323–326.
Pilarski R, Burt R, Kohlman W, Pho L, Shannon KM, Swisher E. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. J Natl Cancer Inst 2013; 105:1607–1616.
Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7:507–515.
Zhou XP, Waite KA, Pilarski R, et al. Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73:404–411.
Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88:42–56.
Ngeow J, Mester J, Rybicki LA, Ni Y, Milas M, Eng C. Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab 2011; 96:E2063–E2071.
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18:400–407.
Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041–4046.
Bertherat J, Horvath A, Groussin L, et al. Mutations in regulatory subunit type 1a of cyclic adenosine 5′-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metabolism 2009; 94:2085–2091.
Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996; 97:699–705.
Stratakis CA, Courcoutsakis NA, Abati A, et al. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997; 82:2037–2043.
Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272:258–262.
Lauper JM, Krause A, Vaughan TL, Monnat R Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One 2013; 8:e59709.
Ishikawa Y, Sugano H, Matsumoto T, Furuichi Y, Miller RW, Goto M. Unusual features of thyroid carcinomas in Japanese patients with Werner syndrome and possible genotype-phenotype relations to cell type and race. Cancer 1999; 85:1345–1352.
Foulkes WD, Priest JR, Duchaine TF. DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 2014; 14:662–672.
de Kock L, Sabbaghian N, Druker H, et al. Germ-line and somatic DICER1 mutations in pineoblastoma. Acta Neuropathol 2014; 128:583–595.
van Engelen K, Villani A, Wasserman JD, et al. DICER1 syndrome: approach to testing and management at a large pediatric tertiary care center. Pediatr Blood Cancer 2018; 65:
Rio Frio T, Bahubeshi A, Kanellopoulou C, et al. DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors. JAMA 2011; 305:68–77.
Slade I, Bacchelli C, Davies H, et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 2011; 48:273–278.
Rath SR, Bartley A, Charles A, et al. Multinodular goiter in children: an important pointer to a germline DICER1 mutation. J Clin Endocrinol Metab 2014; 99:1947–1948.
Rutter MM, Jha P, Schultz KA, et al. DICER1 mutations and differentiated thyroid carcinoma: evidence of a direct association. J Clin Endocrinol Metab 2016; 101:1–5.
Boyce AM and Collins MT. Fibrous Dysplasia/McCune-Albright Syndrome. In: GeneReviews(R), Pagon RA, et al, eds. Seattle, WA: University of Washington, 1993.
Siolek M, Siołek M, Cybulski C, Gąsior-Perczak D, et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J Cancer 2015; 137:548–552.
Verdy M, Weber AM, Roy CC, Morin CL, Cadotte M, Brochu P. Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. J Pediatr Gastroenterol Nutr 1982; 1:603–607.
Decker RA, Peacock ML. Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. J Pediatr Surg 1998; 33:207–214.
Sijmons RH, Hofstra RM, Wijburg FA, et al. Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 1998; 43:542–547.
Brauckhoff M, Machens A, Hess S, et al. Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 2008; 144:1044–1050.
Wray CJ, Rich TA, Waguespack SG, Lee JE, Perrier ND, Evans DB. Failure to recognize multiple endocrine neoplasia 2B: more common than we think? Ann Surg Oncol 2008; 15:293–301.
Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92:4725–4729.
Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995; 43:123–127.
Xu JY, Grubbs EG, Waguespack SG, et al. Medullary Thyroid carcinoma associated with germline RETK666N mutation. Thyroid 2016; 26:1744–1751.
Long KL, Etzel C, Rich T, et al. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer 2017; 16:283–289.
Verhaert N, Vander Poorten V, Delaere P, Bex M, Debruyne F. Levothyroxine replacement therapy after thyroid surgery. B-ENT 2006; 2:129–133.
Said M, Chiu V, Haigh PI. Hypothyroidism after hemithyroidectomy. World J Surg 2013; 37:2839–2844.
McHenry CR, Slusarczyk SJ. Hypothyroidisim following hemithyroidectomy: incidence, risk factors, and management. Surgery 2000; 128:994–998.
Park S, Jeon MJ, Song E, et al. Clinical features of early and late postoperative hypothyroidism after lobectomy. J Clin Endocrinol Metab 2017; 102:1317–1324.
Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) 2009; 71:434–439.
Chambers AJ, Pasieka JL, Temple WJ. Improvement in the accuracy of reporting key prognostic and anatomic findings during thyroidectomy by using a novel Web-based synoptic operative reporting system. Surgery 2009; 146:1090–1098.
Iyer NG, Nixon IJ, Palmer F, Ganly I, Patel SG, Shaha AR. Electronic synoptic operative reporting for thyroid surgery using an electronic data management system: potential for prospective multicenter data collection. Ann Surg Oncol 2011; 18:762–766.
McLaughlin EJ, Brant JA, Bur AM, et al. Safety of outpatient thyroidectomy: review of the American College of Surgeons National Surgical Quality Improvement Program. Laryngoscope 2018; 40:192–202.
Lee DJ, Chin CJ, Hong CJ, Perera S, Witterick IJ. Outpatient versus inpatient thyroidectomy: a systematic review and meta-analysis. Head Neck 2018; 40:192–202.
Snyder SK, Hamid KS, Roberson CR, et al. Outpatient thyroidectomy is safe and reasonable: experience with more than 1,000 planned outpatient procedures. J Am Coll Surg 2010; 210:575–582. 582–4.
Tuggle CT, Roman S, Udelsman R, Sosa JA. Same-day thyroidectomy: a review of practice patterns and outcomes for 1,168 procedures in New York State. Ann Surg Oncol 2011; 18:1035–1040.
Jackson BA, Shelton AJ. Pilot study evaluating topical onion extract as treatment for postsurgical scars. Dermatol Surg 1999; 25:267–269.
Baumann LS, Spencer J. The effects of topical vitamin E on the cosmetic appearance of scars. Dermatol Surg 1999; 25:311–315.
Chung VQ, Kelley L, Marra D, Jiang SB. Onion extract gel versus petrolatum emollient on new surgical scars: prospective double-blinded study. Dermatol Surg 2006; 32:193–197.
Morganroth P, Wilmot AC, Miller C. JAAD online. Over-the-counter scar products for postsurgical patients: disparities between online advertised benefits and evidence regarding efficacy. J Am Acad Dermatol 2009; 61:e31–e47.
Di Donna V, Santoro MG, de Waure C, et al. A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid 2014; 24:1759–1764.
Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249–1252.
Kim MK, Yun KJ, Kim MH, et al. The effects of thyrotropin-suppressing therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. Bone 2015; 71:101–105.
Dowell D, Haegerich TM. Using the CDC guideline and tools for opioid prescribing in patients with chronic pain. Am Fam Physician 2016; 93:970–972.
Brummett CM, Waljee JF, Goesling J, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg 2017; 152:e170504.
Howard R, Fry B, Gunaseelan V, et al. Association of opioid prescribing with opioid consumption after surgery in Michigan. JAMA Surg 2019; 154:e184234.
Tharakan T, Jiang S, Fastenberg J, et al. Postoperative pain control and opioid usage patterns among patients undergoing thyroidectomy and parathyroidectomy. Otolaryngol Head Neck Surg 2019; 160:394–401.
Shindo M, Lim J, Leon E, Moneta L, Li R, Quintanilla-Dieck L. Opioid prescribing practice and needs in thyroid and parathyroid surgery. JAMA Otolaryngol Head Neck Surg 2018; 144:1098–1103.
Mutlu V, Ince I. Preemptive intravenous ibuprofen application reduces pain and opioid consumption following thyroid surgery. Am J Otolaryngol 2019; 40:70–73.
Lou I, Chennell TB, Schaefer SC, et al. Optimizing outpatient pain management after thyroid and parathyroid surgery: a two-institution experience. Ann Surg Oncol 2017; 24:1951–1957.
Dehal A, Abbas A, Hussain F, Johna S. Risk factors for neck hematoma after thyroid or parathyroid surgery: ten-year analysis of the nationwide inpatient sample database. Perm J 2015; 19:22–28.
Dehal A, Al-temimi MH, Abbas AM, et al. Impact of surgeon volume on incidence of neck hematoma after thyroid and parathyroid surgery: ten years’ analysis of nationwide in-patient sample database. Am Surg 2014; 80:948–952.
Rosato L, Avenia N, Bernante P, et al. Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. World J Surg 2004; 28:271–276.
Weiss A, Lee KC, Brumund KT, Chang DC, Bouvet M. Risk factors for hematoma after thyroidectomy: results from the nationwide inpatient sample. Surgery 2014; 156:399–404.
Liu J, Li Z, Liu S, Wang X, Xu Z, Tang P. Risk factors for and occurrence of postoperative cervical hematoma after thyroid surgery: a single-institution study based on 5156 cases from the past 2 years. Head Neck 2016; 38:216–219.
Milone M, Musella M, Conzo G, et al. Thyroidectomy in high body mass index patients: A single center experience. Int J Surg 2016; 28: (suppl 1): S38–S41.
Finel JB, Mucci S, Branger F, et al. Thyroidectomy in patients with a high BMI: a safe surgery? Eur J Endocrinol 2014; 171:99–105.
Shaha AR, Jaffe BM. Practical management of post-thyroidectomy hematoma. J Surg Oncol 1994; 57:235–238.
Chiang FY, Wang LF, Huang YF, Lee KW, Kuo WR. Recurrent laryngeal nerve palsy after thyroidectomy with routine identification of the recurrent laryngeal nerve. Surgery 2005; 137:342–347.
Müller PE, Jakoby R, Heinert G, Spelsberg F. Surgery for recurrent goitre: its complications and their risk factors. Eur J Surg 2001; 167:816–821.
More Y, Shnayder Y, Girod DA, et al. Factors influencing morbidity after surgical management of malignant thyroid disease. Ann Otol Rhinol Laryngol 2013; 122:398–403.
Randolph GW, Shin JJ, Grillo HC, et al. The surgical management of goiter: Part II. Surgical treatment and results. Laryngoscope 2011; 121:68–76.
Zambudio AR, Rodríguez J, Riquelme J, Soria T, Canteras M, Parrilla P. Prospective study of postoperative complications after total thyroidectomy for multinodular goiters by surgeons with experience in endocrine surgery. Ann Surg 2004; 240:18–25.
Qiao N, Wu LF, Gao W, et al. Anatomic characteristics, identification, and protection of the nonrecurrent laryngeal nerve during thyroidectomy. Otolaryngol Head Neck Surg 2017; 157:210–216.
Dzodic R, Markovic I, Santrac N, et al. Recurrent laryngeal nerve liberations and reconstructions: a single institution experience. World J Surg 2016; 40:644–651.
Lee SW, Park KN, Oh SK, Jung CH, Mok JO, Kim CH. Long-term efficacy of primary intraoperative recurrent laryngeal nerve reinnervation in the management of thyroidectomy-related unilateral vocal fold paralysis. Acta Otolaryngol 2014; 134:1179–1184.
Hong JW, Roh TS, Yoo HS, et al. Outcome with immediate direct anastomosis of recurrent laryngeal nerves injured during thyroidectomy. Laryngoscope 2014; 124:1402–1408.
Miyauchi A, Inoue H, Tomoda C, et al. Improvement in phonation after reconstruction of the recurrent laryngeal nerve in patients with thyroid cancer invading the nerve. Surgery 2009; 146:1056–1062.
Hydman J, Björck G, Persson JK, Zedenius J, Mattsson P. Diagnosis and prognosis of iatrogenic injury of the recurrent laryngeal nerve. Ann Otol Rhinol Laryngol 2009; 118:506–511.
Orloff LA, Wiseman SM, Bernet VJ, et al. American Thyroid Association Statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. Thyroid 2018; 28:830–841.
Arer IM, Kus M, Akkapulu N, et al. Prophylactic oral calcium supplementation therapy to prevent early post thyroidectomy hypocalcemia and evaluation of postoperative parathyroid hormone levels to detect hypocalcemia: A prospective randomized study. Int J Surg 2017; 38:9–14.
Sabour S, Manders E, Steward DL. The role of rapid PACU parathyroid hormone in reducing post-thyroidectomy hypocalcemia. Otolaryngol Head Neck Surg 2009; 141:727–729.
Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW. An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg 2010; 34:532–537.
Demeester-Mirkine N, Hooghe L, Van Geertruyden J, De Maertelaer V. Hypocalcemia after thyroidectomy. Arch Surg 1992; 127:854–858.
Thomusch O, Machens A, Sekulla C, Ukkat J, Brauckhoff M, Dralle H. The impact of surgical technique on postoperative hypoparathyroidism in bilateral thyroid surgery: a multivariate analysis of 5846 consecutive patients. Surgery 2003; 133:180–185.
McHenry CR, Speroff T, Wentworth D, Murphy T. Risk factors for postthyroidectomy hypocalcemia. Surgery 1994; 116:641–647.
Cho JN, Park WS, Min SY. Predictors and risk factors of hypoparathyroidism after total thyroidectomy. Int J Surg 2016; 34:47–52.
Asari R, Passler C, Kaczirek K, Scheuba C, Niederle B. Hypoparathyroidism after total thyroidectomy: a prospective study. Arch Surg 2008; 143:132–137.
Docimo G, Ruggiero R, Casalino G, Del Genio G, Docimo L, Tolone S. Risk factors for postoperative hypocalcemia. Updates Surg 2017; 69:255–260.
Giordano D, Valcavi R, Thompson GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid 2012; 22:911–917.
Stack BC Jr, Bimston DN, Bodenner DL, et al. American Association of Clinical Endocrinologists and American College of endocrinology disease state clinical review: postoperative hypoparathyroidism—definitions and management. Endocr Pract 2015; 21:674–685.
Diaz-Soto G, Mora-Porta M, Nicolau J, Perea V, Halperin I, Puig-Domingo M. Efficacy and safety of long term treatment of unresponsive hypoparathyroidism using multipulse subcutaneous infusion of teriparatide. Horm Metab Res 2012; 44:708–710.
Shah M, Bancos I, Thompson GB, et al. Teriparatide Therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism. JAMA Otolaryngol Head Neck Surg 2015; 141:822–827.
Bures C, Klatte T, Gilhofer M, et al. A prospective study on surgical-site infections in thyroid operation. Surgery 2014; 155:675–681.
Gosnell JE, Campbell P, Sidhu S, Sywak M, Reeve TS, Delbridge LW. Inadvertent tracheal perforation during thyroidectomy. Br J Surg 2006; 93:55–56.
Ozer MT, Demirbas S, Harlak A, Ersoz N, Eryilmaz M, Cetiner S. A rare complication after thyroidectomy: perforation of the oesophagus: a case report. Acta Chir Belg 2009; 109:527–530.
Lee SW, Cho SH, Lee JD, Lee JY, Kim SC, Koh YW. Bilateral pneumothorax and pneumomediastinum following total thyroidectomy with central neck dissection. Clin Exp Otorhinolaryngol 2008; 1:49–51.
Koeppen M, Scott B, Morabito J, Fiegel M, Eckle T. Pneumomediastinum and bilateral pneumothoraces causing respiratory failure after thyroid surgery. Case Rep Anesthesiol 2017; 2017:8206970.
Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010; 34:28–35.
Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014; 24:27–34.
Fukuoka O, Sugitani I, Ebina A, Toda K, Kawabata K, Yamada K. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg 2016; 40:529–537.
Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol 2018; 44:307–315.
Oh HS, Ha J, Kim HI, et al. Active surveillance of low-risk papillary thyroid microcarcinoma: a multi-center cohort study in Korea. Thyroid 2018; 28:1587–1594.
Tuttle RM, Fagin JA, Minkowitz G, et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol Head Neck Surg 2017; 143:1015–1020.
Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 2016; 26:144–149.
Venkatesh S, Pasternak JD, Beninato T, et al. Cost-effectiveness of active surveillance versus hemithyroidectomy for micropapillary thyroid cancer. Surgery 2017; 161:116–126.
Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007; 245:366–378.
Tuttle RM, Morris LF, Haugen B, et al, eds. AJCC cancer staging manual. New York: Springer International Publishing, 2017.
Pontius LN, Oyekunle TO, Thomas SM, et al. Projecting survival in papillary thyroid cancer: a comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts. Thyroid 2017; 27:1408–1416.
Adam MA, Thomas S, Roman SA, Hyslop T, Sosa JA. Rethinking the current American Joint Committee on cancer TNM staging system for medullary thyroid cancer. JAMA Surg 2017; 152:869–876.
Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16:109–142.
American Thyroid Association Guidelines Taskforce on Thyroid, N, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167–1214.
Lee SG, Lee WK, Lee HS, et al. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea. Thyroid 2017; 27:174–181.
Hodak S, Tuttle RM, Maytal G, Nikiforov YE, Randolph G. Changing the cancer diagnosis: the case of follicular variant of papillary thyroid cancer-primum non Nocere and NIFTP. Thyroid 2016; 26:869–871.
Xu B, Tallini G, Scognamiglio T, et al. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid 2017; 27:512–517.
Bongiovanni M, Mermod M, Canberk S, et al. Columnar cell variant of papillary thyroid carcinoma: Cytomorphological characteristics of 11 cases with histological correlation and literature review. Cancer 2017; 125:389–397.
Gupta S, Ajise O, Dultz L, et al. Follicular variant of papillary thyroid cancer: encapsulated, nonencapsulated, and diffuse: distinct biologic and clinical entities. Arch Otolaryngol Head Neck Surg 2012; 138:227–233.
Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 2016; 101:264–274.
Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid 2013; 23:1263–1268.
Pezzi TA, Sandulache VC, Pezzi CM, et al. Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head Neck 2016; 38:906–912.
Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Ann Surg Oncol 2012; 19:1874–1880.
DeLellis R, Lloyd RV, Heitz PU, Eng C. WHO/IARC Classification of Tumours. 3rd ed. Vol. 8. Lyon: IARC Press; 2004.
Liu C, Chen T, Liu Z. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Oncol 2016; 14:241.
Prescott JD, Sadow PM, Hodin RA, et al. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 2012; 152:984–990.
Niederer-Wüst SM, Jochum W, Förbs D, et al. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. Surgery 2015; 157:119–125.
Song YS, Lim JA, Choi H, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 2016; 122:1370–1379.
Bullock M, Ren Y, O’Neill C, et al. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin Endocrinol (Oxf) 2016; 85:283–290.
Nicolson NG, Murtha TD, Dong W, et al. Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology. J Clin Endocrinol Metab 2018; 103:2640–2650.
Aragon Han P, Weng CH, Khawaja HT, et al. MicroRNA expression and association with clinicopathologic features in papillary thyroid cancer: a systematic review. Thyroid 2015; 25:1322–1329.
Lang BH, Shek TW, Wan KY. The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol (Oxf) 2017; 86:236–242.
Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16:1229–1242.
Yang Z, Flores J, Katz S, Nathan CA, Mehta V. Comparison of survival outcomes following postsurgical radioactive iodine versus external beam radiation in Stage IV differentiated thyroid carcinoma. Thyroid 2017; 27:944–952.
Fussey JM, Crunkhorn R, Tedla M, Weickert MO, Mehanna H. External beam radiotherapy in differentiated thyroid carcinoma: a systematic review. Head Neck 2016; 38: (suppl 1): E2297–E2305.
Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305–310.
Martinez SR, Beal SH, Chen A, Chen SL, Schneider PD. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010; 102:175–178.
Goffredo P, Robinson TJ, Youngwirth LM, Roman SA, Sosa JA. Intensity-modulated radiation therapy use for the localized treatment of thyroid cancer: Nationwide practice patterns and outcomes. Endocrine 2016; 53:761–773.
Urbano TG, Clark CH, Hansen VN, et al. Intensity Modulated Radiotherapy (IMRT) in locally advanced thyroid cancer: acute toxicity results of a phase I study. Radiother Oncol 2007; 85:58–63.
Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009; 74:1083–1091.
Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 2018; 36:7–13.
Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35:96–112.
Rössing RM, Jentzen W, Nagarajah J, Bockisch A, Görges R. Serum thyroglobulin doubling time in progressive thyroid cancer. Thyroid 2016; 26:1712–1718.
Giovanella L, Trimboli P, Verburg FA, et al. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2013; 40:874–880.
Miyauchi A, Kudo T, Miya A, et al. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 2011; 21:707–716.
Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418–428.
Park S, Kim WG, Song E, et al. Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy. Thyroid 2017; 27:524–530.
Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid 2011; 21:845–853.
Urken ML, Milas M, Randolph GW, et al. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: a multifactorial decision-making guide for the Thyroid Cancer Care Collaborative. Head Neck 2015; 37:605–614.
Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139–1148.
Ríos A, Rodríguez JM, Acosta JM, et al. Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma. Ann Surg Oncol 2010; 17:2444–2451.
Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg 2018; 153:52–59.
Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158:239–246.
Gawlik T, d’Amico A, Szpak-Ulczok S, et al. The prognostic value of tumor markers doubling times in medullary thyroid carcinoma: preliminary report. Thyroid Res 2010; 3:10.
Miccoli P, Frustaci G, Fosso A, Miccoli M, Materazzi G. Surgery for recurrent goiter: complication rate and role of the thyroid-stimulating hormone-suppressive therapy after the first operation. Langenbecks Arch Surg 2015; 400:253–258.
Tan YY, Kebebew E, Reiff E, et al. Does routine consultation of thyroid fine-needle aspiration cytology change surgical management? J Am Coll Surg 2007; 205:8–12.
McCoy KL, Yim JH, Tublin ME, Burmeister LA, Ogilvie JB, Carty SE. Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery 2007; 142:965–972.
Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006; 141:489–494.
Lesnik D, Cunnane ME, Zurakowski D, et al. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. Head Neck 2014; 36:191–202.
Mihailovic J, Prvulovic M, Ivkovic M, Markoski B, Martinov D. MRI versus (1)(3)(1)I whole-body scintigraphy for the detection of lymph node recurrences in differentiated thyroid carcinoma. AJR Am J Roentgenol 2010; 195:1197–1203.
Nascimento C, Borget I, Al Ghuzlan A, et al. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid 2015; 25:437–444.
Lefevre JH, Tresallet C, Leenhardt L, Jublanc C, Chigot JP, Menegaux F. Reoperative surgery for thyroid disease. Langenbecks Arch Surg 2007; 392:685–691.
Farrag TY, Agrawal N, Sheth S, et al. Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma. Head Neck 2007; 29:1069–1074.
Schuff KG, Weber SM, Givi B, Samuels MH, Andersen PE, Cohen JI. Efficacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. Laryngoscope 2008; 118:768–775.
Ondik MP, Dezfoli S, Lipinski L, Ruggiero F, Goldenberg D. Secondary central compartment surgery for thyroid cancer. Laryngoscope 2009; 119:1947–1950.
Roh JL, Kim JM, Park CI. Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol 2011; 18:1312–1318.
Shah MD, Harris LD, Nassif RG, et al. Efficacy and safety of central compartment neck dissection for recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2012; 138:33–37.
Ondik MP, McGinn J, Ruggiero F, Goldenberg D. Unintentional parathyroidectomy and hypoparathyroidism in secondary central compartment surgery for thyroid cancer. Head Neck 2010; 32:462–466.
Lamartina L, Borget I, Mirghani H, et al. Surgery for neck recurrence of differentiated thyroid cancer: outcomes and risk factors. J Clin Endocrinol Metab 2017; 102:1020–1031.
Onkendi EO, McKenzie TJ, Richards ML, et al. Reoperative experience with papillary thyroid cancer. World J Surg 2014; 38:645–652.
Tufano RP, Bishop J, Wu G. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: efficacy, safety, and the association of the BRAF mutation. Laryngoscope 2012; 122:1634–1640.
Sturgeon C, Corvera C, Clark OH. The missing thyroid. J Am Coll Surg 2005; 201:841–846.
Bates MF, Lamas MR, Randle RW, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 2018; 163:118–123.
Salari B, Ren Y, Kamani D, Randolph GW. Revision neural monitored surgery for recurrent thyroid cancer: safety and thyroglobulin response. Laryngoscope 2016; 126:1020–1025.
Chuang YC, Huang SM. Protective effect of intraoperative nerve monitoring against recurrent laryngeal nerve injury during re-exploration of the thyroid. World J Surg Oncol 2013; 11:94.
Barczyński M, Konturek A, Pragacz K, Papier A, Stopa M, Nowak W. Intraoperative nerve monitoring can reduce prevalence of recurrent laryngeal nerve injury in thyroid reoperations: results of a retrospective cohort study. World J Surg 2014; 38:599–606.
Gardner JW. Self-Renewal; the Individual and the Innovative Society. 1st ed. New York: Harper & Row; 1964. xvi, 141 p.

Auteurs

Kepal N Patel (KN)

Division of Endocrine Surgery, NYU Langone Health, New York, NY.

Linwah Yip (L)

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Carrie C Lubitz (CC)

Department of Surgery, Massachusetts General Hospital, Boston, MA.

Elizabeth G Grubbs (EG)

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

Barbra S Miller (BS)

Division of Endocrine Surgery, University of Michigan, Ann Arbor, MI.

Wen Shen (W)

Department of Surgery, University of California San Francisco, San Francisco, CA.

Peter Angelos (P)

Department of Surgery and MacLean Center for Clinical Medical Ethics, The University of Chicago, Chicago, IL.

Herbert Chen (H)

Department of Surgery, University of Alabama at Birmingham, Birmingham, AL.

Gerard M Doherty (GM)

Department of Surgery, Brigham and Women's Hospital, Boston, MA.

Thomas J Fahey (TJ)

Department of Surgery, The New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY.

Electron Kebebew (E)

Department of Surgery and Stanford Cancer Institute, Stanford University, Stanford, CA.

Virginia A Livolsi (VA)

Department of Pathology and Laboratory Medicine, Perelman School of Medicine of University of Pennsylvania, Philadelphia, PA.

Nancy D Perrier (ND)

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.

Jennifer A Sipos (JA)

Division of Endocrinology and Metabolism, The Ohio State University, Columbus, OH.

Julie A Sosa (JA)

Department of Surgery, University of California San Francisco, San Francisco, CA.

David Steward (D)

Department of Otolaryngology, University of Cincinnati College of Medicine, Cincinnati, OH.

Ralph P Tufano (RP)

Division of Head and Neck Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins School of Medicine, Baltimore, MD.

Christopher R McHenry (CR)

MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH.

Sally E Carty (SE)

Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Endocrinologie › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine factuelle › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Maladies endocriniennes › Maladies de la thyroïde › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie des glandes endocrines › Thyroïdectomie › The American Association of Endocrine Surgeons...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › The American Association of Endocrine Surgeons...